Member Announcements 2005

 

December 20, 2005

Angiotech announces Vascular Wrap(TM)/Lifespan(R) Vascular Graft combination product receives designation of “device” for U.S. pivotal study

 

December 20, 2005

WEX Names New CEO and Strengthens Management Team

Vancouver, BC (December 20, 2005) – WEX Pharmaceuticals Inc. (the “Company”) is pleased to announce that Dr. Edge Wang has been named President and Chief Executive Officer of the Company.

 

December 20, 2005

Inflazyme Pharmaceuticals Proceeds with Clinical Phase IIb Asthma Study with IPL512,602

VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) announced today it is proceeding with its Phase IIb clinical study in Q1 2006 with IPL512,602, an oral, once a day, anti-inflammatory medication for the control of asthma.

 

December 20, 2005

Forbes Launches Cholesterol-Lowering Ingredient Reducolâ„¢ in the UK ~Products Incorporating Reducolâ„¢ Destined for UK’s Largest Retailer, Tesco Stores~

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced Forbes’ cholesterol-lowering ingredient, Reducolâ„¢, has been launched in the UK. The initial products carrying Reducolâ„¢ will be sold through the UK’s largest retailer, Tesco Stores Ltd. (Tesco), under their own private label. In combination with Tesco, Forbes Medi-Tech will announce further details about this new line of cholesterol-lowering products early in the new year as they become available on store shelves.

 

December 20, 2005

TECTINâ„¢ Phase IIb/III Interim Analysis Expected

 

December 19, 2005

WEX Appoints New Director

 

December 19, 2005

Angiotech announces new appointments to executive management team

 

December 19, 2005

QSV Biologics, Ltd. and Helix Biopharma Corporation Sign Letter of Intent in Process Development and Manufacture of L-DOS47 Lung Cancer Therapeutic

(Aurora, Ontario) – Helix BioPharma Corp. (Helix; TSX, FSE: “HBP”) today announced that it has signed an agreement with Edmonton, Alberta-based QSV Biologics (QSV) to develop the cGMP manufacturing process for L-DOS47.

 

December 19, 2005

QSV Receives 2005 Frost & Sullivan Customer Value Enhancement Award for Contract Manufacturing Industry

QSV Biologics Ltd. (Edmonton, Canada), has been recognized and awarded the prestigious “2005 Excellence in Customer Value Enhancement (CVE)” best practices award from the global market research consulting firm, Frost & Sullivan (Palo Alto, CA).  The Award presentation was made at the third annual CVE banquet earlier this year in Boston, Massachusetts.

 

December 14, 2005

AMGEN to Acquire ABGENIX for $22.50 / share

THOUSAND OAKS, Calif., and FREMONT, Calif. – (December 14, 2005) – Amgen (Nasdaq: AMGN), the world’s largest biotechnology company, and Abgenix, Inc. (Nasdaq: ABGX), a company specializing in the discovery, development and manufacture of human therapeutic antibodies, today announced that they have signed a definitive merger agreement under which Amgen will acquire Abgenix for approximately $2.2 billion in cash plus the assumption of debt.   Under the terms of the agreement, shareholders of Abgenix will receive $22.50 in cash per common share.

 

December 14, 2005

Protox files IND with U.S. FDA for prostate cancer

Vancouver, British Columbia – Protox Therapeutics Inc. announced today that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for the Company’s lead product, PRX302. Protox plans to initiate Phase 1 clinical trials of PRX302, for the treatment of recurrent localized prostate cancer, early next year, upon approval of the IND by the FDA.

 

December 12, 2005

AnorMED announces 73% of cancer patients who failed prior chemotherapy mobilizations succeed in collecting enough stem cells for transplant

VANCOUVER, Dec. 12 /CNW/ – AnorMED (AMEX: AOM, TSX:AOM) announces the first report of clinical results on MOZOBIL (AMD3100), a first in class stem cell mobilizer, from the compassionate use protocol (CUP) in cancer patients requiring a stem cell transplant. Cancer patients enrolled in the MOZOBIL CUP program failed prior attempts to collect stem cells for transplant using standard mobilization regimens.

 

December 8, 2005

AnorMED Closes $34,500,000 Bought Deal Financing

Vancouver, British Columbia – AnorMED Inc. (AMEX:AOM; TSX:AOM) announced today that it has successfully closed its offering of 8,625,000 Common Shares for gross proceeds of $34,500,000 in connection with the previously announced agreement (the “Underwriting Agreement”) with an underwriting syndicate co-led by Raymond James Ltd. and BMO Nesbitt Burns Inc., and including CIBC World Markets Inc. and Canaccord Capital Corporation.

 

December 8, 2005

ID Biomedical announces closing of acquisition by GlaxoSmithKline

VANCOUVER, Dec. 8 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) (“ID Biomedical”) announced that the acquisition of ID Biomedical by GlaxoSmithKline plc and GlaxoSmithKline Inc. (“GSK”) has now closed and ID Biomedical is now a wholly-owned subsidiary of GSK.

 

December 8, 2005

MIGENIX Completes License Agreement for MX-594AN – Establishes Broad Dermatology Alliance with Cutanea Life Sciences, Inc.

VANCOUVER and PHILADELPHIA, Dec. 8 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, and Cutanea Life Sciences, Inc., (“Cutanea”) a private, dermatological pharmaceutical company based in metropolitan Philadelphia, Pennsylvania, have entered into a License Agreement to develop and commercialize MX-594AN for a number of dermatological indications.

 

December 7, 2005

QLT Announces Repositioning and Streamlining for Future Growth

VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) today outlined a new strategic plan which refocuses the Company on key programs in an effort to enhance shareholder value. This repositioning was initiated by Robert Butchofsky, upon his appointment as acting chief executive officer of QLT in September 2005, and QLT’s executive management team.

 

December 6, 2005

Protox named to TSX Venture 50 list of top emerging companies

Protox Therapeutics Inc. was today named to the 2005 TSX Venture 50â„¢, the first ever ranking of Canada’s top emerging public companies listed on TSX Venture Exchange.

 

December 6, 2005

Perceptronix Announces Appointment of New Directors

VANCOUVER, CANADA (December 6, 2005) – Perceptronix Medical Inc. (“Perceptronix”) announced today the resignation of one member of its Board of Directors and the addition of two new members to its Board of Directors, bringing the total Board membership to six.

 

December 2, 2005

Forbes Medi-Tech Initiates Dosing Phase in Clinical Trial for Cholesterol-Lowering Drug, FM-VP4

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that it has started dosing subjects in a US Phase II trial for its cholesterol-lowering drug, FM-VP4.   The primary efficacy objective of this trial is to determine the effect of two doses of FM-VP4, 450mg and 900mg, given for 12 weeks, compared to placebo, on low density lipoprotein-cholesterol (LDL-C). The goal of this trial is to demonstrate a minimum of 15% reduction from baseline in LDL-C at Week 12. The trial is expected to be completed in the third quarter of 2006.

 

December 1, 2005

Angiotech completes acquisition of Lifespan ® vascular graft product line from Edwards Lifesciences

VANCOUVER, Dec 01, 2005 /PRNewswire-FirstCall via COMTEX/ — Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that it has completed its acquisition of the Lifespan ® ePTFE vascular graft business, located in Laguna Hills, California, from Edwards Lifesciences Corporation (NYSE:EW) for $14 million in cash.

 

November 30, 2005

iCo Therapeutics Announces Strategic Advisory Team

 

November 29, 2005

Protox releases Q3, 2005 Financials

Vancouver, British Columbia- Protox Therapeutics Inc. announced today the release of its third quarter financial statements for the period ending September 30, 2005.

 

November 29, 2005

AnorMED Announces Enrollment of HIV Patients into XACT Study for AMD070 a First in Class CXCR4 HIV Entry Inhibitor

Vancouver, British Columbia – AnorMED Inc. (AMEX:AOM; TSX:AOM) announced today the enrollment of HIV patients into its new clinical trial to evaluate the potential of AMD070 as a new anti-HIV drug.

 

November 24, 2005

Angiotech to webcast conference call discussing third quarter 2005 financial results

VANCOUVER, Oct. 24 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP), will webcast its conference call discussing financial results for the third quarter ended September 30, 2005 on Thursday, November 3rd, 2005 at 2:00 PM PST (5:00 PM EST).

 

November 24, 2005

Protox appoints Dr. James Miller to Board of Directors

Protox Therapeutics Inc. announced today that it has appointed Dr. James Miller to its Board of Directors.

 

November 24, 2005

Chromos Shareholders Approve Acquisition of Targeted Molecules Corporation and Financing Terms

Burnaby, British Columbia, Canada, Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR), today announced shareholder approval of its acquisition of Targeted Molecules Corporation (TMC), provisions for recapitalization of Chromos, and revisions to its incentive stock option plan.

 

November 23, 2005

Inflazyme Announces Results from Helicon’s Phase Ib Multi-Dose Study with PDE4 Inhibitor; IPL455,903 Reported to be Safe and Well Tolerated

VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced preliminary results of the oral, multiple dose Phase I study conducted in healthy volunteers by their partner Helicon Therapeutics, Inc. of New York.

 

November 23, 2005

Inflazyme Pharmaceuticals Names John Hodgman as Chairman of Board of Directors

VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced the appointment of John Hodgman as the Chairman of the Board of Directors effective immediately.   Mr. Hodgman succeeds Dr. Walter Lovenberg who has served as Inflazyme’s Chairman since 1997 and will continue to remain an active member of the Board.

 

November 17, 2005

Inex to Spin Off Targeted Immunotherapy Assets

 

November 17, 2005

Inex Pharmaceuticals Conference Call Notification – Inex to Spin Off Targeted Immunotherapy Assets

VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it will hold a conference call and webcast on Thursday, November 17, 2005 at 1:30 p.m. PST (4:30 pm EST) to provide an update on developments at the Company including the November 17, 2005 announcement to spin-off the Company’s Targeted Immunotherapy assets.

 

November 17, 2005

Protox Completes Oversubscribed $5.8 Million Equity Financing

Vancouver, British Columbia – Protox Therapeutics Inc. announced today that it completed the second and final tranche of a non-brokered private placement, under which Protox issued an aggregate of 11,743,600 units at a price of $0.50 per unit for total gross proceeds of over $5.8 million.

 

November 15, 2005

GenoLogics Receives Frost & Sullivan 2005 Drug Discovery Technologies Award

Victoria, B.C. Canada – GenoLogics Life Sciences Software Inc. (GenoLogics) is proud to have been honored with Frost & Sullivan’s 2005 Drug Discovery Technologies Niche Player of the Year Award   for its success in the systems biology market for the fiscal year 2004.

 

November 14, 2005

Forbes Medi-Tech Announces Third Quarter 2005 Financial Results ~Revenue Increase of 12% in Third Quarter, Company Reaffirms Revenue Guidance~

Vancouver, Canada – Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI) today announced its financial results for the three and nine-month periods ended September 30, 2005.   Comparative periods for these statements are the three months and nine months ended September 30, 2004, respectively. All amounts are in Canadian Dollars unless otherwise noted.

 

November 14, 2005

Cardiome Reports Third Quarter Results

Vancouver, Canada, November 14, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) reported today financial results for the third quarter ending September 30, 2005.   The Company also announced a final decision to suspend further development of Oxypurinol for treatment of congestive heart failure, further to clinical results announced in a press release dated August 15, 2005.

 

November 14, 2005

University of Pittsburgh Genomics and Proteomics Core Laboratories select GenoLogics’ ProteusLIMSâ„¢ lab information and data management system

Victoria, B.C. Canada – GenoLogics Life Sciences Software Inc. (GenoLogics) announced today that the University of Pittsburgh Genomics and Proteomics Core Laboratories (GPCL) have selected ProteusLIMSâ„¢ for   their laboratory information and scientific data management system.

 

November 11, 2005

Cardiome to Release Q3 Results

Vancouver, Canada, November 11, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will report 2005 third quarter financial results the afternoon of Monday, November 14, 2005.   Cardiome will hold a teleconference call and webcast at 4:30pm EST that same day to discuss the results.

 

November 11, 2005

Forbes Medi-Tech Announces Timing of Third Quarter Financial Results

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that it would release its financial results for the third quarter ended September 30, 2005 after market on Monday, November 14, 2005. A conference call and webcast to discuss these financial results will be held on Monday, November 14, 2005 at 1:30pm PT. (4:30pm ET)

 

November 10, 2005

Cardiome to Present RSD1235 Abstract at AHA

Vancouver, Canada, November 10, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that an abstract on its lead antiarrhythmic drug, RSD1235, is scheduled to be presented at the American Heart Association Scientific Sessions meeting to be held in Dallas from November   13-16, 2005.

 

November 10, 2005

TranSenda Announces Addition to Sales Team

Bellevue, WA, November 10, 2005 – TranSenda announced today that Anh Nguyen has joined the Bellevue-based high tech firm.   Ms. Nguyen will be responsible for sales in the Southwestern U.S. region.

 

November 9, 2005

Don Enns named CANTEST Chief Executive Officer

Dr. Don Rix, Chairman of the Board of CANTEST Ltd., is pleased to announce the appointment of Mr. Don Enns as CANTEST’s Chief Executive Officer.

 

November 9, 2005

Abgenix Appoints Jeffrey H. Knapp as Senior Vice President of Sales and Marketing

Abgenix, Inc. (Nasdaq: ABGX) announced today the appointment of Jeffrey H. Knapp to the newly created position of Senior Vice President of Sales and Marketing. In this position, Mr. Knapp will report directly to Bill Ringo, chief executive officer and president of Abgenix, and will be responsible for building and leading Abgenix’s commercial capabilities.

 

November 7, 2005

Inflazyme Announces Financial Results for the Quarter Ended September 30, 2005; Strengthens Financial Position

VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced its second quarter financial results for the period ended September 30, 2005, which reflect the recent corporate reorganization that generated approximately $7 million in non-dilutive funding.

 

November 7, 2005

Protox completes oversubscribed $4.5 million pSelectedrivate placement

Protox Therapeutics Inc. announced today that it completed a non-brokered private placement of 9,091,600 units at a price of $0.50 per unit for total gross proceeds of over $4,500,000.

 

November 7, 2005

GenoLogics advances clinical proteomics research with ProteusLIMS 3.0

 

November 4, 2005

CANTEST Chairman recognized by Entrepreneur of the Year program as Promoter of Entrepreneurship

Dr. Don Rix, Chairman of CANTEST Ltd., received a special citation at last night’s Ernst & Young Entrepreneur of the Year ® national award dinner.

 

November 4, 2005

CANTEST once again named one of the Top 25 companies to work for in British Columbia

CANTEST is proud to announce that it has once again made the list of the province’s Top 25 employers.

 

November 3, 2005

Forbes Medi-Tech to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that Charles Butt, President and CEO, will be presenting at the upcoming Rodman & Renshaw Techvest 7th Annual Healthcare Conference in New York on November 9, 2005.

 

November 2, 2005

Forbes Medi-Tech Initiates US Phase II Trial for Cholesterol-Lowering Drug, FM-VP4

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that it has initiated its US Phase II trial for its cholesterol-lowering drug, FM-VP4. Fifteen US sites have been selected and have begun to identify potentially eligible subjects. The primary efficacy objective of this trial is to determine the effect of two doses of FM-VP4, 450mg and 900mg, given for 12 weeks, compared to placebo, on low density lipoprotein-cholesterol (LDL-C). The goal of this trial is to demonstrate a minimum of 15% reduction from baseline in LDL-C at Week 12.

 

November 2, 2005

Aspreva Pharmaceuticals Reports Third Quarter 2005 Results

Victoria, B.C., Canada; November 2, 2005 – Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV), an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases, today reported business and financial results for the third quarter ended September 30, 2005, highlighted by a continued strong revenue and earnings performance.

 

November 1, 2005

TranSenda Names Ruth Martens Scott Advisory Board Member

Bellevue, WA, November 1, 2005 – TranSenda International, LLC today announced that Ruth Martens Scott, former President of Washington Biotechnology & Biomedical Association (WBBA), has been named to TranSenda’s advisory board.

 

October 31, 2005

Inflazyme to Present at Rodman & Renshaw Techvest 7th Annual Healthcare Conference

 

October 28, 2005

enGene Inc. named recipient of the 2005 Excellence in Research of the Year Award by Frost & Sullivan

Vancouver, BC – 28 October 2005 – enGene Inc., an emerging leader in the field of protein therapeutics, announced today that Frost & Sullivan has awarded the company its 2005 Excellence in Research of the Year Award for development of its innovative Gut Endocrine-cell Modification System (GEMSTM) for application in the field of protein therapeutics in diabetes.

 

October 27, 2005

Inex Pharmaceuticals Receives Positive Court Outcome

VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that the B.C. Supreme Court has dismissed the bankruptcy petition brought forward by Stark Trading and Shepherd Investments International Ltd. (collectively “Stark”).

 

October 27, 2005

Protox announces $4.0 million Equity Financing

Protox Therapeutics Inc. announced today that it is undertaking a non-brokered private placement of 8,000,000 units at a price of $0.50 per unit for total gross proceeds of $4,000,000.

 

October 27, 2005

Forbes Medi-Tech Completes US$6 Million Private Placement

Vancouver, BC – Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI) announced today it has completed a US$6 million Private Placement, resulting in the issuance of Series B Convertible Preferred Shares (preferred shares) with warrants. The preferred shares are convertible at any time, without further consideration, at the option of the holder at a rate of US$1.65 per common share into a total of 3,636,363 common shares, subject to adjustment. The preferred shares mature on October 27, 2008, at which time the Company has the option to redeem the shares at their issue price or convert the preferred shares to common shares at 90% of the date of maturity market price. The warrants entitle the holder to purchase up to 1,818,182 common shares of the Company at a price of US$2.06 per share for five years from the date of closing. Placement proceeds will be used to fund the Company’s pharmaceutical research program and for operational purposes.

 

October 25, 2005

OncoGenex Initiates Fourth Phase 2 Clinical Trial of OGX-011 in Cancer

VANCOUVER, British Columbia, Canada – October 25, 2005 – OncoGenex Technologies Inc. announced today that the first patient has been treated in a Phase 2 clinical trial of OGX-011 in combination with docetaxel in patients with advanced breast cancer.   OGX-011 is a second-generation antisense drug designed to specifically inhibit the production of clusterin, a cell-survival protein associated with resistance to standard anti-cancer treatments.   This clinical trial is designed to assess the safety and efficacy of OGX-011 in combination with docetaxel in women with metastatic or locally advanced breast cancer.  OncoGenex is developing OGX-011 in collaboration with Isis Pharmaceuticals Inc. (NASDAQ:ISIS).

 

October 25, 2005

Perceptronix to Present Lung Cancer Detection Test Clinical Trial Results at International Conference “CHEST 2005″

VANCOUVER, CANADA (October 25, 2005) – Dr. Bojana Turic and Dr. Roger Kemp of Perceptronix Medical Inc. (“Perceptronix”) will each present a paper on the detection of lung cancer by cytometric analysis at “CHEST 2005”, the 71st annual international scientific assembly of the American College of Chest Physicians being held October 29 through November 3 in Montreal, Quebec, Canada.

 

October 24, 2005

Cardiome Acquires Artesian Therapeutics

Vancouver, Canada, October 24, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announced today that it has completed the acquisition of Artesian Therapeutics, Inc., further to the letter of intent (“LOI”) announced on August 29, 2005.

 

October 24, 2005

Aspreva to Release Third Quarter 2005 Financial Results on November 2nd

Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV),an emerging pharmaceutical company focused on increasing the pool of evidence-based medicines available for patients living with less common diseases, announced today that the company will release financial results for the third quarter of 2005 after market close on Wednesday, November 2. The Company will hold a conference call and webcast beginning at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss results and to provide a general corporate update.

 

October 24, 2005

Pacgen Contracts Vancouver-based Syreon for its Phase I/II Clinical Trial of PAC-113 Mouthrinse in HIV Seropositive Patients with Oral Candidiasis

Vancouver, British Columbia, October 24, 2005, Pacgen Biopharmaceuticals Corporation has contracted Syreon Corporation to provide comprehensive clinical trial services for its phase I/II clinical trial of its PAC-113 investigational mouth rinse for the treatment of oral candidiasis.

 

October 24, 2005

Angiotech to webcast conference call discussing third quarter 2005 financial results

 

October 19, 2005

Cardiome and Astellas Initiate ACT 4 Study

Vancouver, Canada, October 19, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. today announced the initiation of an open-label safety study of intravenous RSD1235 for the acute treatment of atrial fibrillation.

 

October 19, 2005

Inimex Selected to Present at Two San Francisco Venture Financing Conferences

Vancouver, B.C., Canada – October 17, 2005. Inimex Pharmaceuticals, Inc. is pleased to announce that it will present at two major life science venture conferences in San Francisco, CA this fall: the BIO InvestorForum (October 19-20) and the National Conference on Biotechnology Ventures (November 14-16).

 

October 19, 2005

Angiotech Pharmaceuticals corporate partner Boston Scientific Corporation recognized as leader in development of rigorous clinical trials

VANCOUVER, BC and WASHINGTON, DC, Oct. 19 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”), today announced that it was recognized by physicians as a leader in the pursuit of evidence-based medicine through increased use of randomized controlled clinical trials. The comments were made during the annual Transcatheter Cardiovascular Therapeutics symposium, in Washington, D.C. The clinical program supporting the BSC’s TAXUS(R) Express(2)(TM) paclitaxel-eluting coronary stent system was cited as the type of definitive medical evidence that physicians should use in making treatment decisions.

 

October 17, 2005

Romel Joins TranSenda as Business Development Executive

Bellevue, WA, October 17, 2005 – TranSenda announced today that Larry Romel, former VP of Clinical Operations for Xcyte Therapies, has joined as Business Development Executive for the Bellevue-based high tech firm.  Mr. Romel brings over twenty years of experience in the life sciences industry.

 

October 17, 2005

Angiotech Pharmaceuticals Appoints Greg Peet to Board of Directors

VANCOUVER, Oct. 17 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,
TSX: ANP), today announced that Greg Peet, a former CEO and Chairman of A.L.I. Technologies Inc, has been appointed to Angiotech’s board of directors.

 

October 12, 2005

OncoGenex Initiates Third of Four Phase 2 Clinical Trials of OGX-011 in Cancer

Study to assess the combined effect of OGX-011 and docetaxel (TAXOTERE ®) in hormone refractory prostate cancer

VANCOUVER, British Columbia, Canada – October 12, 2005 – OncoGenex Technologies Inc. announced that the first patient has been treated in a Phase 2 clinical trial of OGX-011 in hormone refractory prostate cancer patients.   OGX-011 is a second-generation antisense drug designed to specifically inhibit the production of clusterin, a cell-survival protein associated with resistance to standard anti-cancer treatments.   This is the third of four Phase 2 studies OncoGenex has planned for OGX-011 in 2005. OncoGenex is developing OGX-011 in collaboration with Isis Pharmaceuticals Inc. (NASDAQ:ISIS).

 

October 12, 2005

Inex Pharmaceuticals Hearing Completed

VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that the hearing for the bankruptcy petition brought forward by Stark Trading and Shepherd Investments International Ltd. (collectively “Stark”) was completed and the judge has reserved judgment until October 27, 2005.   INEX will report on the final judgment when it is received.

 

October 10, 2005

iCELL Therapeutics receives support from the National Research Council’s Industrial Assistance Program for development of Cancer Treatment

iCell Therapeutics is pleased to announce that it has received support from the National Research Council of Canada’s – Industrial Research Assistance Program (NRC-IRAP) for development of the company’s LDE-TTX technology for treatment of Cancer.

 

October 10, 2005

Angiotech partner to release long-term clinical trial results on market-leading TAXUS(R) Express(2)(TM) coronary stent system at TCT 2005

VANCOUVER, Oct. 10 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner Boston Scientific Corporation (“BSC”) today announced the schedule of their major events and press announcements at the Transcatheter Cardiovascular Therapeutics (TCT) conference, which runs from October 16 to 21 in Washington, D.C. BSC will be announcing long-term efficacy data on its TAXUS(TM) Express(2)(TM) paclitaxel-eluting stent system, including results from the TAXUS I, II, IV and VI clinical trials, as well as data from the ARRIVE, MILESTONE II and OLYMPIA “real-world” registries.

 

October 7, 2005

Angiotech completes acquisition of Afmedica

VANCOUVER, Oct. 7 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,
TSX: ANP) today announced that it has completed its acquisition of Afmedica,
Inc., a private company developing perivascular technology using the drug
rapamycin to treat peripheral vascular disease, coronary artery disease and
end stage renal disease.

 

October 6, 2005

Aspreva and Roche conclude Special Protocol Assessment and reach agreement with FDA

Victoria, B.C., Canada; September 29, 2005 – Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV), today announced that the company and its partner Roche have successfully concluded the special protocol assessment (SPA) with the Cardio-Renal Division of the U.S. Food and Drug Administration (FDA) for the phase III clinical trial of CellCept ® (mycophenolate mofetil) for the treatment of lupus nephritis.

 

October 5, 2005

iCELL Therapeutics to Present at the 2005 BIO InvestorForum

Kito Tosetti, CEO of iCell Therapeutics (www.icelltherapeutics.com), has been selected to present at the Biotechnology Industry Organization’s 2005 InvestorForum in San Francisco.

 

October 5, 2005

Chromos Enters into License Agreement with BD For T-Cell Expansion Patents

Burnaby, British Columbia, Canada: – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) announced today that a patent license has been granted to BD (Becton, Dickinson and Company) (NYSE: BDX), a global medical technology company, under Chromos’ U.S. Patent Number 6,316,257 and 6,890,753 and their foreign counterparts relating to expansion of antigen-specific T-cells.

 

October 4, 2005

Cardiome Appoints Peter W. Roberts as Director

Vancouver, Canada, October 4, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has appointed Peter W. Roberts to the Board of Directors of the Company.

 

October 4, 2005

CANTEST Chairman Named 2005 Entrepreneur Of The Year ® in the Pacific Region Life Sciences Category

Burnaby, British Columbia. Burnaby-based Life Sciences company CANTEST is pleased to announce that Dr. Donald Rix has won the Ernst & Young Entrepreneur Of The Year ® 2005 Pacific Region award in the Health Sciences category.

 

October 3, 2005

Forbes Medi-Tech Receives FDA Clearance to Initiate US Phase II Trial for Cholesterol-Lowering Drug, FM-VP4

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that the FDA has informed Forbes that it may proceed with its Phase II clinical trial of its cholesterol-lowering drug, FM-VP4, as set forth in the Investigational New Drug Application (IND). Forbes plans to initiate the US Phase II trial program later this month.

 

September 30, 2005

SAFC Biosciences and Chromos Announce Strategic Alliance to Co-Market ACE System

  1. LOUIS, MO and BURNABY, BC, CANADA – SAFC Biosciences, a member of the Sigma-Aldrich Group (Nasdaq: SIAL), and Chromos Molecular Systems Inc. (“Chromos”; TSX:CHR), have entered into a non-exclusive co-marketing arrangement whereby SAFC Biosciences   and Chromos will jointly market and offer Chromos’ proprietary ACE System for cell line engineering for protein production applications.

 

September 30, 2005

Cardiome and Astellas Announce Positive Results from Second Phase 3 Trial

Vancouver, Canada, and Deerfield, Illinois, September 29, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM)  and its co-development partner Astellas Pharma US, Inc. today announced results from their recently completed 276-patient atrial arrhythmia Phase 3 clinical study, called ACT 3.  The study achieved its primary endpoint, showing that of the 170 patients with recent-onset atrial fibrillation (AF), 52% of those receiving an IV dose of RSD1235 converted to normal heart rhythm, as compared to 4% of placebo patients (p<0.0001). These percentages are identical to those reported in the first pivotal Phase 3 study, ACT 1.

 

September 30, 2005

Cardiome to Hold Conference Call

Vancouver, Canada, September 29, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will hold a teleconference and webcast on Thursday, September 29th, 2005 at 4:30pm EST (1:30pm PST) to discuss results from the atrial arrhythmia Phase 3 clinical study, called ACT 3 .   A press release will be issued prior to the conference call.

 

September 30, 2005

Angiotech Pharmaceuticals, Inc. Named One of Canada’s Fastest Growing Technology Companies in 2005 Deloitte Canadian Technology Fast 50 Program

VANCOUVER, Sept. 30 /CNW/ – Angiotech Pharmaceuticals, Inc. has been named to Deloitte’s prestigious Canadian Technology Fast 50, the annual program which recognizes excellence, innovation and the fastest growing tech companies in Canada. Rankings are based on percentage of growth in fiscal year revenues over five years, from 2000-2004.

 

September 30, 2005

Angiotech Pharmaceuticals, Inc. Named One of Canada’s Fastest Growing Technology Companies in 2005 Deloitte Canadian Technology Fast 50 Program

VANCOUVER, Sept. 30 /CNW/ – Angiotech Pharmaceuticals, Inc. has been named to Deloitte’s prestigious Canadian Technology Fast 50, the annual program which recognizes excellence, innovation and the fastest growing tech companies in Canada. Rankings are based on percentage of growth in fiscal year revenues over five years, from 2000-2004.

 

September 28, 2005

Inex Pharmaceuticals Receives Notice from Majority Note Holder

VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced that it received notice yesterday that Stark Trading and Shepherd Investments International Ltd. (collectively “Stark”) has filed a petition in the Supreme Court of British Columbia seeking to have INEX declared bankrupt and that a receiving order be made in respect of the property of INEX.

 

September 28, 2005

Phyto-Source Manufacturing Facility Remains Intact After Hurricane Rita

~Production at Pasadena, Texas Joint Venture Facility Resumes~

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that its Phyto-Source manufacturing facility in Pasadena, Texas, a 50-50 joint venture between Forbes and Chusei (USA) Inc., has resumed production of the Company’s cholesterol-lowering ingredients with no apparent material property damage from the recent hurricane activity.

 

September 28, 2005

Angiotech Announces Positive Adhibit Data to Prevent Surgical Adhesions

(NASDAQ: ANPI, TSX: ANP) today announced positive results from a European pivotal clinical study conducted to evaluate the safety and efficacy of Adhibit(TM) Adhesion Prevention Gel for the reduction of surgery induced scars (adhesions) that can occur after surgery to remove fibroids from the uterus (myomectomy surgery).

 

September 27, 2005

Allon “rings bell” to celebrate Toronto Stock Exchange listing

VANCOUVER, Sept. 27 /CNW/ – Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection Company(TM), announced today its Chief Executive Officer and Chief Financial Officer, together with the president of the Toronto Stock Exchange, will ring the bell to open the day’s trading session at the TSX on September 27, 2005. The bell-ringing ceremony marks the debut of Allon’s listing of common shares on the TSX, which began trading on September 21, 2005.

 

September 27, 2005

GenoLogics Expands Management Team to Support Business Growth Strategy

Victoria, B.C. Canada – GenoLogics Life Sciences Software Inc. (GenoLogics) announced today recent additions to its management team in the areas of sales, product development, marketing and finance to support the business expansion and growth strategy of the company.

 

September 23, 2005

Welichem Reports Positive Results with its Lead Anticancer Agent

VANCOUVER, Sept. 23 /CNW/ – Welichem Biotech Inc. (the “Company”) (TSX-V: WBI), a biotechnology company developing therapeutic drugs in the fields of autoimmune diseases and cancer, today announces positive results on the anticancer activity of its WBI-2000 series of compounds.

 

September 22, 2005

Welichem Biotech Inc. Successfully Completes First Annual and Special General Meeting

VANCOUVER, Sept. 22 /CNW/ – Welichem Biotech Inc. (TSX-V:WBI) (“the
Company”) successfully completed its first annual and special general meeting
on September 20, 2005.

 

September 21, 2005

Protox Reports completion of Pre-Clinical Studies for Lead Drug to support Phase I Human Clinical Trials

Protox Therapeutics Inc. announced today that it has successfully completed pre-clinical studies of PRX302 (formerly PSA-PAH1), to support the Company’s planned Phase I human clinical trials in patients with locally recurrent prostate cancer.

 

September 20, 2005

Allon Therapeutics to list shares on the Toronto Stock Exchange

VANCOUVER, Sept. 20 /CNW/ – Allon Therapeutics Inc. (TSX-V:NPC), The Neuro Protection Company(TM), announced today it has received approval to list its common shares on the Toronto Stock Exchange. Trading on the TSX will begin on September 21, 2005 under the trading symbol “NPC”.

 

September 20, 2005

OncoGenex Hires Senior Executives and Establishes U.S. Based Clinical and Regulatory Operations

VANCOUVER, British Columbia, Canada September 20, 2005 – OncoGenex Technologies Inc., a clinical-stage biotechnology company developing targeted therapeutics for the treatment of cancer, announced the appointment of Cindy Jacobs, Ph.D., M.D., to the position of Executive Vice President and Chief Medical Officer and the appointment of Monica Krieger, Ph.D., to Vice President of Regulatory Affairs.  Dr. Jacobs will oversee the advancement of OncoGenex’ pipeline of preclinical and clinical oncology product candidates, and Dr. Krieger will manage the company’s relationship with international regulatory agencies.  Key members from Dr. Jacobs’ previous clinical research, biostatistics and data management groups will also join the OncoGenex team.  Concurrent with the formation of this group, OncoGenex has established U.S. based clinical operations in Seattle, Washington.

 

September 19, 2005

Welichem Biotech Inc. granted Australian Patent for compounds treating autoimmune/inflammatory diseases

VANCOUVER, BC – September 19, 2005 – Welichem Biotech Inc. (TSX-V:WBI) (“the Company”) announced today that the Australian Patent Office has granted the Company a patent (No.780700) covering compounds in the WBI-1000 series that are useful in the treatment of inflammatory/auto-immune diseases such as psoriasis and inflammatory bowel disease.

 

September 13, 2005

Angiotech announces acquisition of Afmedica, Inc.

VANCOUVER, Sept. 13 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) today announced that it has entered into a definitive agreement to acquire Afmedica, Inc., a private company developing perivascular technology using the drug rapamycin to treat peripheral vascular disease, coronary artery disease and end stage renal disease.

 

September 8, 2005

Angiotech partner announces European approval for world’s first “next-generation” drug-eluting stent system

VANCOUVER, Sept. 8 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner Boston Scientific Corporation (“BSC”) today announced that it has received CE Mark for its TAXUS(R) Liberte(TM) paclitaxel-eluting stent system, the world’s first “next-generation” drug- eluting stent system.

 

September 7, 2005

GlaxoSmithKline To Acquire ID Biomedical Corporation

LONDON, PHILADELPHIA, MISSISSAUGA, Ontario, and VANCOUVER, British Columbia, Sept. 7 /CNW/ — GlaxoSmithKline plc (NYSE: GSK) and ID Biomedical Corporation (Toronto: IDB; Nasdaq: IDBE) today announced a definitive agreement for GSK to acquire ID Biomedical, an integrated biotechnology company dedicated to the manufacturing and development of innovative vaccine products, including influenza vaccines. ID Biomedical has facilities in Canada and in the United States.

 

September 7, 2005

MIGENIX Reports First Quarter Fiscal 2006 Results

VANCOUVER and SAN DIEGO, Sept. 7 /PRNewswire-FirstCall/ – MIGENIX Inc. , a clinical-stage developer of drugs for infectious and degenerative diseases, reports financial results for the three months ended July 31, 2005 and an update on its programs.

 

September 7, 2005

Stressgen Granted U.S. Patent Covering Therapeutic Products to Treat Hepatitis B Virus

San Diego, California USA – Stressgen Biotechnologies (“The Company”) (TSX: SSB) announced today that the U.S. Patent and Trademark Office granted Patent Number 6,921,534 covering fusion protein compositions comprised of a hepatitis B virus (HBV) antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins, and methods of treating an HBV infection using these fusion proteins.

 

September 7, 2005

OncoGenex Phase I Study of OGX-011 in Prostate Cancer Meets Primary and Secondary Endpoints

Complete Data from Phase I Study Published in the Journal of the National Cancer Institute
Vancouver, BC Canada – September 7, 2005 – OncoGenex Technologies announced today that data from a completed Phase I study of OGX-011, a cancer drug found to sensitize tumours to standard therapy, is well tolerated and reduces clusterin expression in primary prostate cancers in humans.   Clusterin is a protein found in tumour cells that, when over expressed, causes resistance to cell death induced by standard anti-cancer therapies.   The study concluded that OGX-011, targeted to clusterin, can be safely given to humans in therapeutic doses that inhibit clusterin expression in cancer tissues resulting in increased cancer cell death.   Primary and secondary objectives were achieved with statistical significance of OGX-011 in prostate cancer.

 

September 6, 2005

Cardiome to Present at Investor Conferences

Vancouver, Canada, September 6, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that the Company will participate in two upcoming investor conferences.   Bob Rieder, President & CEO, will present at the 18th Annual Bear Stearns Healthcare Conference at the Grand Hyatt Hotel in New York City on Tuesday, September 13th at 3:30pm EST.   Mr. Rieder will also present at the UBS Global Life Sciences Conference at the Grand Hyatt Hotel in New York City on Tuesday, September 27th at 3:30pm EST.   Live webcasts of both presentations will be available on Cardiome’s website at www.cardiome.com.

 

September 1, 2005

Angiotech Pharmaceuticals to participate in Thomas Weisel Healthcare Conference

VANCOUVER, Sept. 1 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the Thomas Weisel Healthcare Tailwinds Conference.

 

August 31, 2005

Forbes Medi-Tech Submits IND Application for Cholesterol-Lowering Drug, FM-VP4

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to initiate a US Phase II clinical trial for its cholesterol-lowering drug, FM-VP4. The application provides the FDA with clinical and preclinical safety and manufacturing data in support of clinical evaluation of FM-VP4 in humans.

 

August 31, 2005

Providence Health Care researcher appointed to the Order of Canada

August 31, 2005 – Dr. James C. Hogg, a researcher at Providence Health Care’s iCAPTURE Centre, was appointed Monday as an Officer of the Order of Canada. Dr. Hogg is one of the best-known pulmonary pathologists in the world. He has made major contributions to the understanding of lung disease, and continues to pursue an active research program.

 

August 31, 2005

Cardiome Successfully Completes RSD1235 Oral Phase 1 Trial

Vancouver, Canada, August 31, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has successfully completed the Phase 1 studies required to advance oral RSD1235 into a planned Phase 2 study later this year.   The most recently completed study evaluated the pharmacokinetics (PK), safety and tolerability of orally-administered RSD1235 over 7 days of repeat dosing within an escalating dose regimen.

 

August 30, 2005

MIGENIX Announces Initiation of MX-226 Phase III Clinical Study

VANCOUVER and SAN DIEGO, Aug. 30 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, today announced the initiation of United States enrollment in a multi-national Phase III clinical study with MX-226 (also known as CPI-226), a compound in development for the prevention of  catheter-related infections.

 

August 29, 2005

Allon Therapeutics Completes $6.3 million financing

VANCOUVER, Aug. 29 /CNW/ – Allon Therapeutics Inc. (TSX-V:”NPC”), The Neuro Protection Company(TM), announced today that it has completed the previously announced private placement of common shares to a group of largely institutional investors at a price of $1.05 per share for gross proceeds of $6.3-million.

 

August 29, 2005

Cardiome Announces Letter of Intent to Acquire Artesian Therapeutics

Vancouver, Canada, August 29, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announced today that it has executed a letter of intent (“LOI”) to acquire Artesian Therapeutics, Inc., a privately held U.S. biopharmaceutical company.  Headquartered in Gaithersburg, Maryland, Artesian was founded in March of 2002 to discover and develop bi-functional small-molecule drugs for the treatment of cardiovascular disease.

 

August 26, 2005

Perceptronix Announces Appointment of Stephen Anderson as Chief Financial Officer

VANCOUVER, CANADA (August 26, 2005) – Perceptronix Medical Inc. (“Perceptronix”), a cancer diagnostics medical device company, announced today the appointment of Stephen Anderson as Chief Financial Officer.

 

August 25, 2005

WEX Completes Investigators’ Meeting

Vancouver, BC (August 25, 2005) – WEX Pharmaceuticals Inc. (WEX or the Company) today announced the completion of the first of three scheduled investigators’ meetings for the re-launch of its Phase IIb/III clinical trial of Tectin for the treatment of moderate to severe cancer-related pain.

 

August 25, 2005

Canadian Genomics Researchers Receive $346 Million For New Projects in Health, Agriculture, Forestry and Fisheries

WINNIPEG, August 25, 2005 – The Honourable David L. Emerson, Minister of Industry and Minister responsible for Genome Canada, and Dr. Cal Stiller, Chairman of the Board of Genome Canada, today announced 33 new genomics and proteomics research projects totalling $346 million. Of this, $167.2 million is provided by Genome Canada and $179.3 million by Canadian and international partners.

 

August 25, 2005

Perceptronix Annunces that Results of Lung Cancer Detection Test Clinical Trial Meet Test Objectives

VANCOUVER, CANADA (August 25, 2005) – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has unblinded its clinical trial for the ClearSignâ„¢ Test, a non-invasive test for the detection of lung cancer based on the automated cytometric analysis of sputum. Initial analysis indicates that the clinical trial met all significant objectives and the Company is optimistic that licenses will be issued for the ClearSignâ„¢ Test early in 2006.

 

August 25, 2005

Isis Pharmaceuticals Licenses Antisense Drug to iCo Therapeutics for the Treatment of Eye Diseases

Vancouver, BC, August 29, 2005–Isis Pharmaceuticals, Inc. and iCo Therapeutics Inc. announced that Isis has granted an exclusive worldwide license to iCo for the development and commercialization of ISIS 13650, a second-generation antisense drug. iCo will initially develop ISIS 13650 for the treatment of various eye diseases caused by the formation of new blood vessels (choroidal neovascularization) such as age-related macular degeneration (AMD) and diabetic retinopathy.

 

August 24, 2005

Wex to Present Two Posters at the 11th World Congress on Pain

Vancouver, BC (August   24, 2005) – WEX Pharmaceuticals Inc. (WEX or the Company) is pleased to announce  that Dr. Kim Fisher, Senior Research Scientist for WEX, is presenting two posters at the 11th World Congress on Pain being held this week in Sydney, Australia.

 

August 24, 2005

GenoLogics Solution Provides Powerful Capability to help Proteomics Researchers in Biomarker Discovery and Data Analysis

Victoria, B.C. Canada – GenoLogics Life Sciences Software Inc. (GenoLogics), a leading developer of solutions that help research and pharmaceutical laboratories manage, integrate and analyze enormous volumes of scientific data, announced today added functionality to its ProteusLIMSâ„¢ solution, making it the most powerful system available on the market to speed biomarker discovery and validation in proteomics and systems biology.

 

August 23, 2005

Forbes Medi-Tech Makes Valuable Addition to the Board of Directors

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) announced today the appointment of Guy Miller, CEO of Edison Pharmaceuticals, to the Forbes Medi-Tech Board of Directors.

 

August 22, 2005

Allon begins dosing in Phase I human trial of second product for mild cognitive impairment

VANCOUVER, Aug. 22 /CNW/ – Allon Therapeutics Inc. (TSX-V:”NPC”), The Neuro Protection Company(TM), announced today it has commenced dosing the first patient in a Phase I human clinical trial to evaluate the Company’s second product AL-208 as an intravenous treatment for mild cognitive impairment (MCI) associated with post-coronary artery bypass graft (CABG) surgery. Clinical drug development experts estimate this market to be $3 billion for which there is no available treatment today.

 

August 18, 2005

WEX Announces the Results of the Phase IIa Opioid Withdrawal Study

 

August 17, 2005

Appointment of Interim Chief Financial Officer

Vancouver, BC (August 17, 2005) – WEX Pharmaceuticals Inc. (WEX or the Company) today announced that Michael Perri, Chief Financial Officer, has resigned from his position with the Company for personal reasons.   A search for a replacement is currently underway.   In the meantime, the Board of Directors has appointed Michael Chen, MBA, CPA, as interim CFO.   Mr. Chen will serve the Company on a part-time basis until a permanent successor is named.

 

August 16, 2005

OncoGenex Announces Completion of $12.8 Million Venture Financing

VANCOUVER, Aug. 16 /CNW/ – OncoGenex Technologies Inc., a clinical-stage biotechnology company developing targeted therapeutics for the treatment of cancer, announced the completion of a $12.8 million (U.S.) oversubscribed series B2 round of private equity financing with participation from several leading venture capital firms.

 

August 16, 2005

Allon reports Second Quarter operating results

VANCOUVER, Aug. 16 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), reported today in its second quarter 2005 operating results that it achieved all of its performance milestones, including positive results from its Phase Ia human clinical trial evaluating lead product AL-108 as a treatment for Alzheimer’s disease and preparations to begin a Phase Ib clinical trial in Q3 2005.

 

August 16, 2005

American Journal of Cardiology Study Finds TAXUS Has Lower MACE Rate Than Cypher

VANCOUVER, Aug. 16 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”), today welcomed the results of an independent study demonstrating that BSC’s TAXUS(R) Express2(TM) paclitaxel- eluting stent system had lower incidents of major adverse cardiac events (MACE) than Johnson & Johnson’s Cypher(R) sirolimus-eluting stent system. The results of the study were published in the August 1 edition of the American Journal of Cardiology.

 

August 16, 2005

WEX Seeks a New CEO

Vancouver, BC (August 16, 2005) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”) today announced that the Company is seeking a new Chief Executive Officer to take the company to the next level.

 

August 15, 2005

Cardiome Reports Clinical Results From OPT-CHF Study

Vancouver, Canada, August 15, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced results from its Phase 2 clinical trial evaluating Oxypurinol in 405 congestive heart failure (“CHF”) patients.   The study, called OPT-CHF, measured the clinical impact of 600mg daily oral dosing of Oxypurinol for 24 weeks on the clinical outcomes in New York Heart Association (“NYHA”) Class 3 and Class 4 CHF patients receiving standard CHF therapy.   Oxypurinol failed to demonstrate a statistically significant benefit over placebo in the primary composite endpoint (p=0.357).

 

August 15, 2005

Allon Therapeutics arranges $6.2 million financing

VANCOUVER, Aug. 15 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), announced today that it has arranged a $6.2-million private placement of common shares to a group of largely institutional investors at a price of $1.05 per share. The placement funds have been received and closing is expected in the immediate future upon formal TSX Venture Exchange acceptance.

 

August 15, 2005

ID Biomedical announces 2005 second quarter release date and conference call

VANCOUVER, Aug. 10 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ:IDBE) announced today that it will report its 2005 second quarter results on Monday August 15, 2005 at 4:00 pm Eastern, 1:00 pm Pacific. The Company will hold a conference call/web cast at 5:00 pm Eastern, 2:00 pm Pacific. The call can be accessed by dialing (604) 677-8677 or by logging onto the Company’s website at www.idbiomedical.com

 

August 15, 2005

WEX Annual and Special Meeting Update

Vancouver, BC (August 15, 2005) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”) today announced the results of its Annual and Special Meeting of Shareholders held on August 12, 2005.

 

August 12, 2005

Cardiome to Hold Conference Call

Vancouver, Canada, August 12, 2005 — Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will hold a teleconference and webcast on Monday, August 15th, 2005 at 9:00am EST (6:00am PST) to discuss top-line results from the Phase 2 OPT-CHF Congestive Heart Failure trial.   A press release will be issued prior to the conference call.

 

August 12, 2005

Allon Therapeutics to present at Orion Securities’ 10th Annual Healthcare Conference

VANCOUVER, Aug. 12 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), announced that its President and Chief Executive Officer, Gordon McCauley, will present at the Orion Securities’ 10th Annual Health Conference on August 15 in Mont Tremblant, Quebec. The presentation is scheduled to take place at 2:30 p.m. ET at the Hotel Club Tremblant and will provide updates on the company’s performance milestones, research and clinical drug development programs.

 

August 11, 2005

News!

News!

 

August 11, 2005

INEX Releases Second Quarter 2005 Operating Results

VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) reported today in its second quarter 2005 operating results that the appointment of a new president and the restructuring to conserve cash announced June 21, 2005 will allow the Company to extract value from its anticancer drug Marqiboâ„¢, its other Targeted Chemotherapy cancer products and its early-stage Targeted Immunotherapy pipeline.

 

August 11, 2005

Ondine Biopharma Announces 2005 Second Quarter Financial Results

VANCOUVER, Aug. 11 /CNW/ – Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP) (“Ondine”) announced today its financial results for the second
quarter ended June 30, 2005.

 

August 10, 2005

Debenture Redemption Request and Negotiations

Vancouver, BC (August 10, 2005) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”) today announced that the Company is in discussions regarding its unsecured convertible debentures in the aggregate principal amount of US$5.1 million that were issued in June 2004 by the Company’s wholly owned subsidiary, Wex Medical Limited, to 3 investment funds managed by a major Asian financial institution (“Institution”).

 

August 5, 2005

Angiotech Pharmaceuticals, Inc. Announces Results For The Second Quarter Ended June 30, 2005

VANCOUVER, August 4, 2005 — Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) today announced financial results for the second quarter ended June 30, 2005. Amounts, unless specified otherwise, are expressed in U.S. dollars.

 

August 4, 2005

Angiotech Pharmaceuticals, Inc. announces results for the second quarter ended June 30, 2005

VANCOUVER, Aug. 4 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI;TSX: ANP) today announced financial results for the second quarter ended June 30, 2005. Amounts, unless specified otherwise, are expressed in U.S. dollars.

 

August 2, 2005

Chromos Makes Payment on Debenture

BURNABY, BC, Aug. 2 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) announced that it issued 1,294,526 common shares in payment of interest and $1,500,000 of the principal amount owing for the convertible debenture issued to CellExSys Inc. (“CellExSys”) shareholders during the 2004 acquisition of CellExSys.

 

August 1, 2005

Abgenix and Amgen Announce FDA Grants Panitumumab Fast Track Designation for Metastatic Colorectal Cancer

THOUSAND OAKS, Calif. and FREMONT, Calif., Aug. 1 /PRNewswire-FirstCall/ — Amgen (Nasdaq: AMGN) and Abgenix, Inc. (Nasdaq: ABGX) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for panitumumab, an experimental fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFr), for patients with metastatic colorectal cancer who have failed standard chemotherapy treatment.

 

July 28, 2005

Angiotech to webcast conference call discussing second quarter 2005 financial results

VANCOUVER, July 28 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP), will webcast its conference call discussing financial results for the second quarter ended June 30th, 2005 on Thursday, August 4th, 2005 at 2:00 PM PST (5:00 PM EST).

 

July 28, 2005

Angiotech to webcast conference call discussing second quarter 2005 financial results

VANCOUVER, July 28 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP), will webcast its conference call discussing financial results for the second quarter ended June 30th, 2005 on Thursday, August 4th, 2005 at 2:00 PM PST (5:00 PM EST).

 

July 27, 2005

Angiotech Pharmaceuticals to participate in Adams Harkness Conference

VANCOUVER, July 27 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the 25th Annual Adams Harkness Summer Seminar Conference.

 

July 26, 2005

Allon to proceed with Phase I human clinical trial for second product

VANCOUVER, July 26 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company, announced today it will begin Phase I human clinical trials next month evaluating its second drug product AL-208 intended as a treatment for mild cognitive impairment (MCI) associated with cardiac artery bypass graft (CABG) surgery, a $3 billion market for which there is no available treatment today.

 

July 26, 2005

Strategic Review Results in Special Charges

FREMONT, Calif., July 26 /PRNewswire-FirstCall/ — Abgenix, Inc. (Nasdaq: ABGX) today reported financial results for the second quarter ended June 30, 2005. In light of the special charges resulting from the completion of a strategic review and restructuring during the second quarter, the company is presenting financial results under generally accepted accounting principles (GAAP) and non-GAAP for the period. A reconciliation of the GAAP and non-GAAP financial results is set forth at the end of this press release.

 

July 25, 2005

StemCell Technologies brings design and production of RoboSepTM back to Canada

Vancouver, BC,     July 25, 2005 — StemCell Technologies, Inc. (Vancouver, BC) announced today that StarFish Medical (Victoria, BC) has been chosen to finish the design work and to be the responsible manufacturer of the RoboSepâ„¢, the first instrument to offer true walk-away automation of magnetic cell separation.

 

July 21, 2005

Angiotech Pharmaceuticals to participate in Banc of America Conference

VANCOUVER, July 21 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the Banc of America Securities 2005 Specialty Pharmaceuticals Conference.

 

July 21, 2005

Perceptronix Receives ISO (International Organization for Standardization) Quality Certification

 

July 19, 2005

Perceptronix Granted Another U.S. Patent For Lung Cancer Detection Technology

 

July 14, 2005

Chromos Strengthens Intellectual Property Estate with Four New Patents

BURNABY, BC, July 14 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) announced today that it has further expanded the patent portfolio surrounding both its ACE System and REM Technology with the issuance of four key additional patents. Chromos was awarded patents from the United States, Canada and Australia relating to its chromosome-based gene delivery and expression technology known as the ACE System as well as an additional United States patent relating to its REM Technology.

 

July 12, 2005

ID Biomedical’s flu vaccine granted Fast Track status by FDA

VANCOUVER, July 12 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today it has been advised by the United States Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) that the Company’s Influenza Virus Vaccine (Fluviral(TM)) has been granted a Fast Track designation.

 

July 12, 2005

Expiry Dates for Warrants Extended

Vancouver, BC (July 12, 2005) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”) today announced that the TSX has approved the extension of the expiry dates of 3,838,788 previously issued share purchase warrants (“Warrants”) for an additional one-year period, subject to shareholder approval, where required.   The Company believes that the extension of the expiry dates is in its best interest, as this will increase the likelihood that the Warrants will be exercised.

 

July 7, 2005

Welichem Biotech Inc. announces changes to Board of Directors

VANCOUVER, July 7 /CNW/ – Welichem Biotech Inc. (TSX-V:WBI) (“the Company”) announced changes to its Board of Directors today. John R. North has resigned from the Board of Directors due to other business commitments. John Dustan, a retired senior portfolio manager, has been named to replace him.

 

July 6, 2005

Shareholders Rights Plan Adopted

Vancouver, BC (July 6, 2005) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”) announced that it has adopted a shareholder rights plan (the “Rights Plan”) designed to encourage the fair treatment of its shareholders in the event of an unsolicited take-over bid for shares of the Company.   The Rights Plan will provide the board of directors (the “Board) and shareholders of the Company with more time to fully consider any unsolicited take-over bid without undue pressure, allowing the Board to pursue, if appropriate, other alternatives to maximize shareholder value and allowing additional time for competing bids to emerge.

 

June 30, 2005

Allon Director Resigns to Accept New Position

VANCOUVER, June 30 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company, announced today that one of its Directors, Mr. Isaac Kohlberg, has resigned. Mr. Kohlberg recently began a new role as Associate Provost and Chief Technology Development Officer of Harvard University. Given the nature of his new role responsible for technology transfer at Harvard, Mr. Kohlberg has decided it is appropriate to resign rather than risk any potential conflicts.

 

June 29, 2005

WEX Reports Year End Financial Results

Vancouver, BC (June 29, 2005) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”) reported today highlights and financial results for the fiscal year ended March 31, 2005.   All amounts, unless specified otherwise, are in Canadian dollars.

 

June 28, 2005

Abgenix to Consolidate Research Facilities in Preparation for Expanded Development and Commercial Operations

FREMONT, Calif., June 28 /PRNewswire-FirstCall/ — Abgenix, Inc. (Nasdaq: ABGX) today announced that the company is consolidating its research and pre-clinical activities into the company’s Canadian facility in Burnaby, British Columbia. With the consolidation, Abgenix maintains appropriate research capabilities and capacity to meet its future internal needs, as well as those of its partners.

 

June 28, 2005

Patent No. ZL95190556.2

Vancouver, BC (June 28, 2005) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”) announced that it has been notified that based on a court ruling (the “Ruling”) the Chinese Patent Office (“CPO”) has changed registered ownership of the drug withdrawal Patent No. ZL95190556.2 “Use of Amino Quinazoline Hydride Compound and its Derivative for Abstaining from Drug Dependence” in China from the Company’s subsidiary, Nanning Maple Leaf Pharmaceuticals (“NMLP”) to one of the two inventors and a third party who alleges to have been an employer of the other inventor.

 

June 24, 2005

ARC Pharmaceuticals Inc. Presents Data at the 21st Annual Meeting of the European Society of Human Reproduction and Embryology

Vancouver, British Columbia – ARC Pharmaceuticals Inc. announced today that it presented a scientific poster entitled “Cisplatin-loaded Films Reduce Adhesion Formation in the Rat” at the 21st Annual Meeting of the European Society of Human Reproduction and Embryology held in Copenhagen, Denmark, June 19-22.

 

June 21, 2005

INEX Announces Restructuring Plan and Appoints New President and COO

Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) today announced extensive management changes and a restructuring to conserve cash and to facilitate a new strategic path to advance its lead anticancer drug Marqiboâ„¢, its other Targeted Chemotherapy cancer products and its promising early-stage Targeted Immunotherapy pipeline. Timothy M. Ruane has been appointed President and Chief Operating Officer (COO), effective immediately.

 

June 20, 2005

Angiotech partner completes first enrollment phase in next-generation TAXUS(R) Liberte(TM) coronary stent system registry

VANCOUVER, June 20 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner Boston Scientific Corporation (“BSC”) today announced that it has completed enrollment in the transitional phase of the world’s largest drug-eluting stent registry. The OLYMPIA registry plans to enroll more than 30,000 patients at more than 600 centers in the United States, Europe and other international locations.

 

June 20, 2005

Allon files IND to begin clinical trials for second product AL-208

VANCOUVER, June 20 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company, announced today it has filed an Investigational New Drug application (IND) with the United States Food and Drug Administration (FDA) seeking approval to begin human clinical trials evaluating the company’s second product AL-208 as a treatment for for the mild cognitive impairment (MCI) associated with cardiac artery bypass surgery.

 

June 15, 2005

Allon Therapeutics product AL-108 successful in Phase Ia clinical trial

VANCOUVER, June 15 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), announced today that a Phase Ia human clinical trial of the company’s first product AL-108 has demonstrated that a single dose administered at up to 15 milligrams was safe and well tolerated in healthy adults. AL-108 is being developed as a treatment for Alzheimer’s disease.

 

June 14, 2005

Allon Therapeutics to present science and clinical updates at Washington and Philadelphia conferences

VANCOUVER, June 14 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), announced today it will present updates of the company’s preclinical research and clinical drug development programs at conferences in the United States June 19th and June 22nd.

 

June 9, 2005

StemCell Technologies signs worldwide distribution deal for ALDEFLUORâ„¢ with StemCo Biomedical

Vancouver, BC, June 9, 2005 – StemCell Technologies, Inc. today announced that it has signed a worldwide distribution agreement with StemCo Biomedical, Inc. whereby StemCell Technologies will distribute StemCo’s ALDEFLUORâ„¢ product.   StemCell Technologies had previously distributed ALDEFLUOR only in the Americas and the Asia-Pacific territory (excluding Japan).

 

June 7, 2005

Welichem Biotech Inc. completes $1.95 million private placement

VANCOUVER, BC – June 7, 2005 – Welichem Biotech Inc. (TSX-V:WBI) (“the Company”) is pleased to announce that it has completed a private placement of $1.95 million concurrent with its listing on the TSX-V where shares began trading Wednesday, May 25, 2005.

 

June 7, 2005

Perceptronix Announces Election of Board of Directors

 

June 2, 2005

Angiotech to host year-in-review presentation from 2005 annual general meeting of shareholders

VANCOUVER, June 2 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) will host a live webcast of a year-in-review presentation to shareholders at its annual general meeting on Thursday, June 9, 2005 beginning at 9:00 am PST (12:00 pm EST). The annual general meeting will be held at The Hyatt Regency Hotel in Vancouver, BC, Canada. The presentation will be hosted by Dr. William Hunter, President and Chief Executive Officer of Angiotech.

 

June 2, 2005

Angiotech announces formation of a venture initiative

VANCOUVER, June 2 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced the formation of a new division focused on venture stage investing and new venture relationship development and management, Angiotech Drug Device Venture and Capital Enterprises (ADDVANCE). ADDVANCE intends to commit capital of up to $50 million over the next three years to development stage companies and new enterprises.

 

June 2, 2005

Angiotech licenses ChondroGEL(TM) to Histogenics for use in cartilage and orthopedic tissue regeneration applications

VANCOUVER, June 2 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced the execution of a license agreement to Histogenics Corporation for the use of Angiotech’s proprietary biomaterial ChondroGEL(TM) in the field of cartilage, ligament, meniscus and/or tendon repair, including related osteochrondal defects.

 

June 2, 2005

Angiotech broadens Paclitaxel franchise with license to Broncus Technologies for novel treatment of emphysema

VANCOUVER, June 2 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced the execution of a license agreement with Broncus Technologies, Inc. This agreement allows Broncus Technologies to incorporate Angiotech’s pioneering Paclitaxel technology with their Exhale(R) system to treat emphysema.

 

June 2, 2005

Allon animal study confirms blood brain barrier penetration of lead product candidates AL-108 and AL-208

VANCOUVER, June 2 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), announced today that new preclinical animal studies have confirmed that its lead product candidates AL-108 and AL-208 penetrate the blood brain barrier and reach their target therapeutic areas in the central nervous system.

 

June 2, 2005

Protocol Amendment Approved by Health Canada

Vancouver, BC (June 2, 2005) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”) is pleased to announce that it has received a No Objection Letter (NOL) from Health Canada to amend the Phase IIb/III clinical trial protocol for Tectinâ„¢ in moderate to severe inadequately controlled cancer-related pain.

 

June 1, 2005

Angiotech updates 2005 and 2006 financial outlook

VANCOUVER, June 1 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) today announced its updated 2005 and 2006 financial projections. These will be presented at its annual analyst meeting tomorrow in New York City where Angiotech will be providing updates with respect to clinical, corporate development and financial plans.

 

May 30, 2005

Chromos enters into ACE System license agreement with Pfizer

 

May 27, 2005

Allon reports First Quarter 2005 operating results

VANCOUVER, May 27 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), today reported in its First Quarter 2005 operating results that it achieved its key quarterly milestones, including the launch and completion of its Phase Ia human clinical trial evaluating lead product AL-108 as a treatment for Alzheimer’s disease.

 

May 26, 2005

Angiotech partner announces 400th patient enrolled in study of next-generation TAXUS(R) Liberte(TM) coronary stent system

VANCOUVER, BC, and PARIS, France, May 26 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”), today announced that BSC has enrolled its 400th patient in the world’s largest drug-eluting stent registry. The global TAXUS Liberte registry plans to enroll more than 30,000 patients at more than 600 centers in the United States, Europe and other international locations.

 

May 26, 2005

ID Biomedical announces webcast of 2005 Annual General Meeting of Shareholders

VANCOUVER, May 26 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today that it will be holding its Annual General Meeting of Shareholders at 2:30 pm (ET), today, Thursday May 26, 2005 at the Fairmont Queen Elizabeth Hotel in Montreal, QC. A web cast of the meeting can be heard by accessing the Company’s website atwww.idbiomedical.com. The web cast of the meeting will be archived and available on the Company’s website through August 22, 2005.

 

May 26, 2005

Syreon/Novartis Partnership Leads BC Clinical Research Services Industry

 

May 26, 2005

New Director of Intellectual Property

Vancouver, BC (May 26, 2005) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”) is pleased to announce that Dr. Euan Taylor has accepted the position of Director of Intellectual Property with the Company.   Dr. Taylor has a B.A in Natural Sciences from the University of Cambridge, a Ph.D. in developmental molecular biology from the University of London and a law degree from the University of British Columbia.   He is also a registered Canadian Patent Agent and a Registered Canadian Trademark Agent.

 

May 25, 2005

Trial results support safety for next-generation Taxus(R) Liberte(TM) paclitaxel-eluting stent system

VANCOUVER and PARIS, France, May 25 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”), today announced thirty-day safety data from BSC’s ATLAS clinical trial. ATLAS is the first trial using BSC’s new Liberte(TM) coronary stent as a platform for its paclitaxel-eluting coronary stent system.

 

May 25, 2005

TAXUS V sub-population data further support efficacy of TAXUS(R) Express(2)(TM) stent system in diabetic patients

VANCOUVER and PARIS, France, May 25 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”), today announced nine-month sub-population data from its TAXUS V clinical trial that further supports the efficacy of the TAXUS(R) Express(2)(TM) paclitaxel- eluting coronary stent system for the treatment of coronary artery disease in diabetic patients.

 

May 25, 2005

Chromos signs letter of intent to acquire Targeted Molecules and secures bridge financing facility

BURNABY, BC, May 25 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”) (TSX:CHR) has entered into a Letter of Intent to acquire Targeted Molecules Corporation (“TMC”), a privately held San Diego based biotechnology company focused on the research and development of two antibody product candidates for treatment of multiple sclerosis and acute thrombosis.

 

May 24, 2005

Moderate-release TAXUS(R) Express(2)(TM) coronary stent system demonstrates excellent durability in high-risk patients out to two years

VANCOUVER, BC and PARIS, France May 24 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”), today announced two-year follow-up data from BSC’s TAXUS VI clinical trial. The data demonstrated that the safety and efficacy benefits associated with a moderate-release formulation of the TAXUS(R) Express(2)(TM) paclitaxel-eluting stent system were maintained at two years.

 

May 24, 2005

TAXUS V IVUS results support safety and efficacy in most challenging lesions and highest-risk patients

VANCOUVER and PARIS, FRANCE, May 24 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”), today announced intravascular ultrasound (IVUS) follow-up data from BSC’s TAXUS V clinical trial, supporting the safety and efficacy of the TAXUS(R) Express(2)(TM) paclitaxel-eluting coronary stent system for the treatment of coronary artery disease in the most challenging lesions and highest-risk patients ever studied in a randomized, controlled clinical trial in the United States.

 

May 24, 2005

Allon presents pre-clinical data to European neuroscience forum

VANCOUVER, May 24 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), has presented pre-clinical data to a prominent European neuroscience forum that helps explain how the company’s proprietary lead compounds protects brain cells from degenerative diseases.

 

May 24, 2005

Ondine Biopharma Completes C$12,000,000 Equity Financing

 

May 24, 2005

Welichem Biotech Inc. Commences Trading on the TSX Venture Exchange

VANCOUVER, BC — May 24, 2005 – Welichem Biotech Inc. (TSX-V:WBI) (“the Company”) is pleased to announce that it will begin trading under the symbol “WBI” on the TSX Venture Exchange at the market open, Wednesday, May 25, 2005.

 

May 22, 2005

FDA approves 12-month shelf life for TAXUS(R) stent system

VANCOUVER, May 22 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”), today announced that the U.S. Food and Drug Administration (FDA) has approved extending the shelf life of BSC’s TAXUS(R) Express(2)(TM) paclitaxel-eluting coronary stent system in the United States to twelve months from the current shelf life of nine months.

 

May 20, 2005

Angiotech partner to release broad range of clinical trial results on market-leading TAXUS(R) EXPRESS2(TM) coronary stent system…

VANCOUVER, May 20 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”), today announced the schedule of BSC’s major events and press announcements at the Paris Course on Revascularization (EuroPCR), which runs from May 24 to 27 in Paris.

 

May 20, 2005

ID Biomedical announces webcast of 2005 Annual General Meeting of Shareholders

VANCOUVER, May 20 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today that it will be holding its Annual General Meeting of Shareholders at 2:30 pm (ET), on Thursday May 26, 2005 at the Fairmont Queen Elizabeth Hotel in Montreal, QC. A web cast of the meeting can be heard by accessing the Company’s website atwww.idbiomedical.com. The web cast of the meeting will be archived and available on the Company’s website through August 22, 2005.

 

May 20, 2005

Abgenix to Present at Needham & Company’s Fourth Annual Biotechnology Conference

FREMONT, Calif., May 20 /PRNewswire-FirstCall/ — Abgenix, Inc. (Nasdaq: ABGX) today announced that it will present at Needham & Company’s Fourth Annual Biotechnology Conference on Thursday, May 26, 2005 at 10:30 a.m. PT / 1:30 p.m. ET. The presentation will be webcast live and may be accessed by visiting the Abgenix website at www.abgenix.com. A replay of the webcast will also be available on the company’s website until Thursday, June 9, 2005.

 

May 18, 2005

Allon Therapeutics to present at BioFinance 2005 conference

VANCOUVER, May 18 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), announced it will present at BioFinance 2005, Canada’s leading life sciences investor conference held in Toronto May 17-19.

 

May 18, 2005

Ondine Biopharma Prices Cdn$12,000,000 Million Equity Financing

VANCOUVER, May 18 /CNW/ – Ondine Biopharma Corporation (TSX:OBP) (AIM:OBP) (the “Company”) announced today that in connection with the previously announced filing of a preliminary short form prospectus in the provinces of British Columbia, Alberta, Manitoba, Saskatchewan and Ontario relating to the offering in such provinces of common shares and the private placement of such securities in the United States, the United Kingdom and selected jurisdictions in Europe, it has entered into an agency agreement with Canaccord Capital Corporation and Sprott Securities Inc. to offer, on a commercially reasonable efforts basis, 6,000,000 common shares from treasury at a price of Cdn$2.00 (Pounds Sterling 0.85) per common share for gross proceeds of Cdn$12,000,000. The securities commissions in the above provinces issued a final receipt for the prospectus on May 17, 2005.

 

May 17, 2005

Angiotech Pharmaceuticals to participate in 2005 UBS Global Pharmaceuticals Conference

VANCOUVER, May 17 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the 2005 UBS Global Pharmaceuticals Conference.

 

May 17, 2005

INEX Presents Marqiboâ„¢ Clinical Data at Medical Meetings

VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today results from clinical studies indicating its lead anticancer drug, Marqiboâ„¢, has shown anti-tumor activity in patients with relapsed non-Hodgkin’s lymphoma (NHL), Hodgkin’s disease and pediatric malignancies.

 

May 16, 2005

Cardiome Reports First Quarter Results

Vancouver, Canada, May 16, 2005 – Cardiome Pharma Corp. (NASDAQ-CRME, COM-TSX) reported today financial results for the first quarter ended March 31, 2005. Amounts, unless specified otherwise, are in Canadian dollars. At close of business on March 31, 2005, the exchange rate was CDN$1.00 = U.S. $0.8267.

 

May 16, 2005

Zymeworks announces its move to a new office and the expansion of its team

Vancouver, Canada – Zymeworks Inc., a privately held Canadian company, has moved from its former office at the Forintek building on the University of British Columbia campus to a more central location at 201-1401 West Broadway. Recently, Zymeworks added three key members to its team: Dr. Oanh Dang as Business Development Manager, Dr. Gregory Chasse as Molecular Physics Lead, and Dr. John Vieceli as Molecular Simulations Lead.

 

May 16, 2005

Cardiome selected for Nasdaq Biotechnology Index

Vancouver, Canada, May 16, 2005 Cardiome Pharma Corp (Nasdaq: CRME) (TSX: COM) today announced that it has been selected to become a member of the NASDAQ Biotechnology Index ® (Nasdaq: NBI – News). Cardiome’s inclusion in the index will become effective with the market open on Monday, May 23, 2005.

 

May 16, 2005

ID Biomedical reports 2005 first quarter results

VANCOUVER, May 16 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today financial results for the quarter ended March 31, 2005. Amounts, unless specified, are expressed in Canadian dollars.

 

May 16, 2005

Forbes Medi-Tech Announces Financial Results for the Quarter Ended March 31, 2005

VANCOUVER, British Columbia–(BUSINESS WIRE)–May 16, 2005–Forbes Medi-Tech Inc. (TSX:FMI – News; NASDAQ:FMTI – News) today announced its financial results for the three months ended March 31, 2005. Comparative period for these statements is the three months ended March 31, 2004. All amounts are in Canadian Dollars unless otherwise noted.

 

May 13, 2005

Kinexus Bioinformatics Corporation honored as a recipient of Red Herring’s Top 100 Private Companies

VANCOUVER, May 13 /CNW/ – Kinexus Bioinformatics Corporation, a Canadian proteomics company, was recently honored by Red Herring as one of the Top 100 Private Companies in North America. The award winning Silicon Valley media company selected Kinexus from over 900 companies based on its demonstrated critical contributions in novel technologies and services and its innovative business strategy.

 

May 12, 2005

Abgenix Appoints Marc Better, Ph.D., as Vice President of Process Sciences

FREMONT, Calif., May 11 /PRNewswire-FirstCall/ — Abgenix, Inc. (Nasdaq: ABGX), a biopharmaceutical company focused on development of antibody therapeutics, announced today the appointment of Marc Better, Ph.D., as Vice President of Process Sciences.

 

May 12, 2005

Aspreva Pharmaceuticals Reports First Quarter 2005 Results and Provides Guidance

VICTORIA, BC, May 12 /CNW/ – Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV), an emerging pharmaceutical company focused on identifying, developing and commercializing new indications for approved drugs and drug candidates for underserved patient populations, today reported business and financial results for the first quarter ended March 31, 2005. Unless otherwise specified, all amounts are in U.S. dollars and are reported under U.S. GAAP.

 

May 12, 2005

OncoGenex to Present New Phase 1 Data on Lead Cancer Drug Candidate OGX-011 at 2005 ASCO Annual Meeting

VANCOUVER, May 12 /CNW/ – OncoGenex Technologies announced today that results from a second Phase 1 study of OGX-011, the company’s lead product candidate, will be presented at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO) to be held May 13-17, 2005, in Orlando, Florida. OGX-011 is being co-developed by OncoGenex and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS).

 

May 12, 2005

Neuromed Technologies Expands Executive Team with the Addition of Dr. Barry Sachais, Mr. Sean Cunliffe and Dr. Simon Li

VANCOUVER, May 12 /CNW/ – Neuromed Technologies Inc., a biopharmaceutical company developing a new generation of chronic pain drugs, today announced the appointment of Dr. Barry Sachais to Vice President, Clinical Development, Mr. Sean Cunliffe to Vice President, Commercial Development and Dr. Simon Li to Vice President, Medical Research. All three positions are newly created.

 

May 12, 2005

Angiotech Pharmaceuticals to participate in Banc of America Health Care Conference 2005

VANCOUVER, May 12 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the Banc of America Health Care Conference 2005.

 

May 12, 2005

Cardiome to release q1 results

Vancouver, Canada, May 12, 2005 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that it will report its first quarter financial results at 11 am EST, 8 am PST on Monday May 16th. Cardiome will then hold a teleconference and webcast at 1:30 pm EST, 10:30 am PST that same day to discuss the results.

 

May 11, 2005

INEX Releases First Quarter 2005 Operating Results

VANCOUVER, BC, May 11 /CNW/ – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today in its first quarter 2005 operating results that progress is being made on a new commercialization path for its lead anticancer drug Marqibo(TM). The Company also accomplished some important objectives to extract value from its pipeline products, including advancing its next product, INX-0125, towards clinical trials.

 

May 11, 2005

ID Biomedical announces 2005 first quarter release date and conference call

VANCOUVER, May 11 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today that it will report its 2005 first quarter results on Monday, May 16, 2005 at 4:00 pm Eastern. The Company will follow the results with a conference call/web cast at 5:00 pm Eastern / 2:00 pm Pacific. The call can be accessed by dialing (604) 677-8677 or by logging onto the Company’s website at www.idbiomedical.com.

 

May 11, 2005

Ondine Biopharma Announces 2005 First Quarter Financial Results

VANCOUVER, May 11 /CNW/ – Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) (“Ondine”) announced today its financial results for the three-month period ended March 31, 2005.

 

May 10, 2005

Stressgen Biotechnologies Announces First Quarter Financial Results

San Diego, California USA -Stressgen Biotechnologies (“The Company”) (TSX: SSB) announced today financial results for the first quarter ended March 31, 2005. All amounts, unless specified otherwise, are in Canadian dollars.

 

May 9, 2005

StemCell Technologies Announces the Release of their 2005/2006 Catalog

StemCell Technologies announces the release of their 2005/2006 catalog

 

May 5, 2005

enGene Inc. co-founder to be interviewed on Canada’s top-rated financial radio broadcast

Vancouver, BC – 5 May 2005 – On Saturday morning May 7th, Dr. John C. Brown will join Michael Campbell, host of the MoneyTalks radio program (www.moneytalks.net), in studio for a conversation that will be aired across Canada on the CORUS radio network. The program is aired live in Vancouver on CKNW, AM 980 between 8:30am and 10:00am Pacific time. The show and interview can also be heard live on the internet at www.cknw.com.

 

May 5, 2005

WEX Announces Departure of General Manager

Vancouver, BC (May 5, 2005) – WEX Pharmaceuticals Inc. (WEX or the Company) announced today the departure of John Olthoff, General Manager, as a consequence of corporate restructuring of the Company. John will continue to remain as a Director of WEX. Mr. Olthoff became a Director and was appointed the General Manager of the Company in the year 2000 bringing over 30 years of operational experience.

 

May 4, 2005

Angiotech announces positive safety data

VANCOUVER, May 4 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced positive preliminary safety results from its novel and proprietary Vascular Wrap(TM) paclitaxel-eluting mesh trial. This first-in- man study is designed to evaluate the safety and performance of a novel and proprietary drug-loaded Vascular Wrap in the prevention of stenosis after peripheral bypass surgery.

 

May 4, 2005

Angiotech Pharmaceuticals, Inc. Announces Results for the Quarter Ended March 31, 2005

VANCOUVER, May 4, 2005 — Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) today announced financial results for the first quarter ended March 31, 2005. Amounts, unless specified otherwise, are expressed in U.S. dollars.

 

May 4, 2005

Notification of INEX’s Annual General Meeting Webcast and First Quarter Operating Results Conference Call

VANCOUVER, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX:IEX) announced today that it will webcast its Annual General Meeting on May 10, 2005 and it will hold a conference call and webcast for its first quarter 2005 operating results on May 11, 2005.

 

May 3, 2005

Angiotech partner announces first international trial of a paclitaxel-eluting stent for peripheral artery disease

VANCOUVER, May 3 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Cook Inc., today announced that with a U.S. trial already underway, Cook Group will expand its efforts to bring the world’s first paclitaxel-eluting stent for peripheral artery disease (PAD) to market by launching an international clinical trial. The global clinical investigation of Cook’s Zilver(R) PTX Drug-Eluting Stent will enroll 760 patients at up to 50 investigational sites in Europe, Asia, Australia and Canada.

 

May 3, 2005

Celator Pharmaceuticals(SM) Closes $40 Million Financing

PRINCETON, N.J., May 3 /CNW/ — Celator Pharmaceuticals, Inc., a privately held North American biopharmaceutical company, has closed a $40 million (U.S.) round of private equity financing with participation from several leading venture capital firms. The financing, representing one of the largest venture capital investments in biotechnology in both Canada and the United States during the past 12 months, will support Celator’s expanding research and product development efforts targeting new combination chemotherapies to treat different forms of cancer.

 

May 3, 2005

Providence Health Care researcher named one of Canada’s Top 40 Under 40TM

May 3, 2005-A researcher at Vancouver’s Providence Health Care has been named one of Canada’s Top 40 Under 40TM. The award was founded by executive search firm The Caldwell Partners to honour Canadians who have reached a significant level of success before age 40.

 

May 2, 2005

Forbes Medi-Tech Announces Product Launch with Kesko of Finland

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that Kesko of Finland has launched a range of yogurts incorporating Forbes’ cholesterol-lowering ingredient, Reducol(tm). The yogurt, sold under the “Pirkka” premium brand name, is the first in a series of scheduled product launches planned for later this year incorporating Forbes’ cholesterol-lowering ingredient into a variety of food matrices.

 

May 2, 2005

QLT Announces TSX Approval of US $50 Million Share Repurchase Program

VANCOUVER, CANADA–QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced that the Toronto Stock Exchange has accepted notice of QLT’s intention to make a normal course issuer bid in the open market through the facilities of the Toronto Stock Exchange and/or the NASDAQ Stock Market announced on April 28, 2005.

 

May 2, 2005

Aspreva To Hold First Quarter 2005 Results Conference Call on May 12

VICTORIA, BC, May 2 /PRNewswire-FirstCall/ – Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV – News; TSX: ASV – News) announced today that it will release financial results for the first quarter of 2005 after market close on May 12 and will hold a conference call and webcast beginning at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss those results and to provide a general corporate update.

 

April 28, 2005

Phase 3 Clinical Trial Initiated to Evaluate the Use of Panitumumab Therapy For First-Line Treatment of Metastatic Colorectal Cancer

THOUSAND OAKS, Calif. and FREMONT, Calif., April 26 /PRNewswire-FirstCall/ — Amgen Inc. (Nasdaq: AMGN) and Abgenix, Inc. (Nasdaq: ABGX) today announced the initiation of a Phase 3 clinical study to evaluate the potential benefits of adding panitumumab, an experimental fully human monoclonal antibody, administered every other week to bevacizumab (Avastin(TM), Genentech) and either oxaliplatin- (Eloxatin(R), sanofi-aventis) or irinotecan-based (Camptosar(R), Pfizer) chemotherapy for the first-line treatment of metastatic colorectal cancer.

 

April 28, 2005

QLT announces Q1 results for 2005 and reiterates guidance

VANCOUVER, April 28 /PRNewswire-FirstCall/ – QLT Inc. (NASDAQ: QLTI – News; TSX: QLT – News) today reported financial results for the first quarter ended March 31, 2005. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

 

April 28, 2005

Allon Therapeutics selected to present at Beyond Science 2005 conference

VANCOUVER, April 28 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), announced today it is among 20 companies invited to present April 28th at Beyond Science 2005 in Washington, D.C. The conference is sponsored by ASM Resources, Inc. (ASMR), the venture-arm of the American Society for Microbiology, the oldest and largest single-life-science membership organization in the world.

 

April 28, 2005

Migenix receives approval to initiate MX-4509 Phase I/II study

VANCOUVER, BC and SAN DIEGO, CA, April 28 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has received a Letter of Authorization from Health Canada for a clinical trial application (CTA) to begin a Phase I/II human clinical study with MX-4509, a compound in development for the treatment of neurodegenerative diseases.

 

April 28, 2005

ARC Pharmaceuticals Selected to Present at Invest Northwest 2005

VANCOUVER, April 28 /CNW/ – ARC Pharmaceuticals Inc. announced today that Chris Springate, President, was invited to present at Invest Northwest, a life sciences and CEO investor conference, held April 26-27, 2005 at the Bell Harbor Conference Center in Seattle, Washington.

 

April 27, 2005

Stressgen implements restructuring to focus resources on advancing its lead product candidate HspE7 to market

VICTORIA, BC, and SAN DIEGO, CA, April 27 /CNW/ – Stressgen Biotechnologies (TSX:SSB) announced today a restructuring that will allow the Company to focus its resources on the advancement of its lead product candidate, HspE7, for human papillomavirus (HPV)-related diseases.

 

April 27, 2005

Twinstrand Therapeutics Inc. today announces initiation of Phase I trial for TST10088 in patients with advanced solid tumours

BURNABY, BC, April 27 /CNW/ – Twinstrand Therapeutics Inc. today announced that it has initiated a Phase I clinical trial for TST10088 in patients with advanced solid tumours at Princess Margaret Hospital in Toronto, Canada. TST10088, Twinstrand’s lead compound, is a novel, proprietary, targeted prodrug for treatment of solid tumour forms of cancer.

 

April 26, 2005

Angiotech Pharmaceuticals to participate in Deutsche Bank Conference

VANCOUVER, April 26 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI, TSX: ANP), is scheduled to participate in the 30th Annual Deutsche BankHealthcare Conference.

 

April 26, 2005

Protox releases 2004 financial statements

Protox Therapeutics Inc. announced today the release of its year end financial statements for the period ending December 31, 2004.

 

April 26, 2005

Allon Therapeutics selected by the Alzheimer’s Disease Cooperative Study

VANCOUVER, April 26 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), announced today that its Alzheimer’s clinical development program has been selected by the Alzheimer’s Disease Cooperative Study (ADCS) in the United States to be included in its submission to receive Phase II clinical trial funding from the U.S. National Institutes of Health (NIH).

 

April 26, 2005

OncoGenex Announces In-Licensing and Development Plans for a Novel Cancer Therapeutic

VANCOUVER, April 26 /CNW/ – OncoGenex Technologies Inc., announced today that it has in-licensed the rights to inhibitors of heat shock protein 27 (Hsp27) from The University of British Columbia. Additionally, Hsp27 has been accepted by Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) as a collaboration target under the expanded OncoGenex/Isis antisense drug discovery agreement announced earlier this year.

 

April 25, 2005

Stressgen appoints Gregory M. McKee to Board of Directors

SAN DIEGO, April 25 /CNW/ – Stressgen Biotechnologies (TSX:SSB) announced today that at a meeting of the Company’s Board of Directors held April 12, 2005, the Board appointed Gregory M. McKee as a director of the Company effective immediately. The appointment was made concurrently with the appointment of Mr. McKee as President and Chief Executive Officer of the Company.

 

April 25, 2005

Cardiome successfully completes second phase 1 trial

Vancouver, Canada, April 25, 2005 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that it has successfully completed the Phase 1b study for its controlled-release oral formulation of RSD1235. The completed study evaluated the safety and efficacy of oral RSD1235 as a function of fed and fasted states in normal and poor metabolizers. The study confirmed that RSD1235 is well absorbed and tolerated in all subjects.

 

April 22, 2005

iCell Therapeutics to Present at Invest Northwest 2005, April 27

VANCOUVER, British Columbia, April 22 /PRNewswire/ — Kito Tosetti, CEO ofiCell Therapeutics (will present at the WashingtonBiotechnology & Biomedical Association’s (WBBA) Invest Northwest, a lifesciences and CEO investor conference on Wednesday, April 27, 2005.

 

April 22, 2005

enGene to Present at the Invest Northwest CEO and Investor Forum April 26 – 27, 2005

Vancouver, BC, Canada – April 22, 2005 – enGene, Inc., a private, preclinical-stage biotechnology company, will be presenting at the Invest Northwest CEO and Investor Forum in Seattle, WA. Eric A. Adams, President and CEO will provide a corporate overview and update of the current activities of the company, with a focus on the many significant near-term milestones for enGene’s diabetes program.

 

April 21, 2005

QLT Announces Visudyne Sales for First Quarter of 2005

VANCOUVER, CANADA—QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that its alliance partner, Novartis, announced global Visudyne ® (verteporfin) sales of approximately US$123.7 million for the quarter ended March 31, 2005. This represents an increase of 22.5% over sales in the first quarter of 2004.

 

April 21, 2005

Cardiome to Present at Invest Northwest

Vancouver, Canada, April 21, 2005 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that Bob Rieder, President & CEO, will present at the Invest Northwest conference on Tuesday April 26th.

 

April 20, 2005

Angiotech partner announces publication of six TAXUS IV articles in prestigious Journal of American College of Cardiology

VANCOUVER, April 20 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner Boston Scientific (“BSC”) today announced that six articles related to its pivotal TAXUS IV clinical trial were published in the April 19 edition of the prestigious Journal of American College of Cardiology (JACC), with the launch of a special issue devoted to the TAXUS IV trial.

 

April 20, 2005

Asia-Based Manufacturing Partner Invests in Perceptronix

VANCOUVER, CANADA (April 20, 2005) – Perceptronix Medical Inc. (“Perceptronix”), a Vancouver-based medical device company focused on cancer diagnostics, announced today that it has closed the private placement with Speed Fair Co. Ltd. (“Speed Fair”) of Hong Kong   referred to in its press release of 7 April, 2005.   Speed Fair has purchased units comprised of Perceptronix common shares and subscription warrants, giving Speed Fair an initial equity position of just over 5% of the currently issued and outstanding common shares of Perceptronix.

 

April 19, 2005

Allon Therapeutics compounds show potential to repair central nervous system cells after disease or injury

VANCOUVER, April 19 /CNW/ – Two proprietary compounds of Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), have the potential to become new treatments that contribute to development and repair of central nervous system cells damaged by neurodegenerative disease or injury, according to results of a preclinical study published in the March issue of the Journal of Molecular Neuroscience.

 

April 18, 2005

Abgenix to Host Conference Call on First Quarter 2005 Financial Results

FREMONT, Calif., April 18 /PRNewswire-FirstCall/ — Abgenix, Inc. (Nasdaq: ABGX) will hold a conference call on Tuesday, April 26, 2005 at 1:30 p.m. PT, 4:30 p.m. ET, to discuss first quarter financial results and to provide an update on the company’s antibody discovery, development, and manufacturing activities. Bill Ringo, president and chief executive officer of Abgenix, will host the call.

 

April 18, 2005

Protox Announces Change to Senior Management

Monday, April 18th, 2005 – Vancouver, British Columbia – Protox Therapeutics Inc. announced today that Dr. Fahar Merchant has been appointed President and CEO of the Company, replacing Tazdin Esmail who has stepped down for health reasons. Mr. Esmail will continue to sit on the Board of the Company as a director and will provide ongoing guidance as a consultant.

 

April 18, 2005

Wex Pharmaceuticals Appoints New Director and Chairman of the Board

Vancouver, BC (April 18, 2005) – WEX Pharmaceuticals Inc. (WEX or the Company) is pleased to announce the appointment of Mr. Guang Luan as Director and Chairman of its Board of Directors.

 

April 15, 2005

Abgenix Announces Data Presentations for Panitumumab at AACR and ASCO Annual Meetings

FREMONT, Calif., April 15 /PRNewswire-FirstCall/ — Abgenix, Inc. (Nasdaq: ABGX) today announced upcoming presentations of clinical and preclinical data from studies of panitumumab, a fully human monoclonal antibody currently in pivotal clinical trials as a third line monotherapy in colorectal cancer, will be presented at the American Association for Cancer Research (AACR) annual meeting April 16-20 in Anaheim, California and the 41st American Society of Clinical Oncology (ASCO) annual meeting May 13-17 in Orlando, Florida.

 

April 14, 2005

Allon Therapeutics presents at European BioSquare partnering conference

VANCOUVER, April 14 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), is today presenting an update of the company’s clinical development program and overall business strategy at Biosquare 2005, a life sciences partnering conference in Lyon, France.

 

April 14, 2005

Angiotech partner announces FDA approval and launch of Liberte(TM) coronary stent system

VANCOUVER, April 14 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI, TSX: ANP) corporate partner Boston Scientific Corporation (“BSC”) todayannounced that it has received U.S. Food and Drug Administration (FDA)approval for its Liberte(TM) bare-metal coronary stent system which will serveas the platform for BSC’s next-generation U.S. paclitaxel-eluting stentsystem, TAXUS(R) Liberte(TM). BSC plans to launch the product immediately inthe United States.

 

April 13, 2005

Stressgen announces appointment of new President and Chief Executive Officer

VICTORIA, BC, and SAN DIEGO, CA, April 13 /CNW/ – Stressgen Biotechnologies (TSX:SSB) announced today that it has appointed Gregory M. McKee as the Company’s President and Chief Executive Officer.

 

April 13, 2005

Stressgen announces sale of bioreagents business for approximately C$8.0 million and withdraws preliminary prospectus for offering of common shares

VICTORIA and SAN DIEGO, April 13 /CNW/ – Stressgen Biotechnologies (TSX:SSB) (“the Company”) announced today that that it has signed a definitive agreement to sell its bioreagents business to Stressgen Bioreagents Corporation, a newly-formed company funded by Ampersand Ventures (“Ampersand”), for approximately C$8.0 million.

 

April 12, 2005

Allon reports 2004 audited operating results

VANCOUVER, April 12 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), reported today its 2004 audited operating results. The Company met all of its publicly stated milestones in 2004 and subsequently has met all of its year-to-date 2005 milestones.

 

April 12, 2005

Angiotech partner announces start of enrollment in groundbreaking clinical trial comparing drug-eluting stents to cardiac surgery

VANCOUVER, April 12 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI, TSX: ANP) corporate partner Boston Scientific Corporation (“BSC”) todayannounced that enrollment has begun in its clinical trial known as SYNTAX,which will compare the performance of drug-eluting stents with cardiac surgeryin the most complex patient subsets: those with coronary artery disease in allthree coronary arteries, in the left main coronary artery, or both.

 

April 11, 2005

Ondine Biopharma announces filing of preliminary short-form prospectus

VANCOUVER, April 11 /CNW/ – Ondine Biopharma Corporation (TSX:OBP) (AIM:OBP) (“the Company”), announced today it has filed a preliminary short form prospectus in certain provinces of Canada to qualify, on a commercially reasonable efforts basis, the offering through Canaccord Capital Corporation and Sprott Securities Inc. of common shares of the Company.

 

April 11, 2005

Pacgen Biopharmaceuticals Retains Dow Pharmaceutical Sciences for PAC-113 Phase I/II Human Clinical Trials

Vancouver, B.C., Canada, April 11, 2005 – Pacgen Biopharmaceuticals Corporation (“Pacgen”) announced today it has retained Dow Pharmaceutical Sciences (“Dow”), a leading clinical manufacturing and research organization (CMO/CRO) for regulatory, clinical, manufacturing and distribution services for its PAC-113 phase I/II human clinical trials.

 

April 8, 2005

MIGENIX to Present Celgosivir Data for the Treatment of Hepatitis C at the 18th International Conference on Antiviral Research

VANCOUVER, BC, CANADA & SAN DIEGO, CA, USA, April 8 /CNW/ – MIGENIX Inc., (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, will present three posters on the Company’s Phase II alpha-glucosidase I inhibitor, celgosivir (MX-3253), in development for the treatment of chronic Hepatitis C Virus (“HCV”) infections.

 

April 7, 2005

ARC Pharmaceuticals Inc. Receives US Patent

VANCOUVER, April 7 /CNW/ – ARC Pharmaceuticals Inc. (ARC) announced today that The University of British Columbia (UBC) has been granted a new US patent entitled “Pharmaceutical Compositions and Methods Relating to Fucans, No. 6,812,220. The patent protects key intellectual property exclusively licensed to ARC that may be used in the development of ARC’s lead product candidates for the treatment of surgical adhesions.

 

April 7, 2005

Cardiome reports final oxypurinol clinical results

Vancouver, Canada, April 7, 2005 Cardiome Pharma Corp (Nasdaq: CRME) (TSX: COM) today announced the release of final results for the physician-sponsored “EXOTIC-EF” clinical study for oxypurinol in congestive heart failure (CHF) patients. The 20-patient study showed a statistically-significant improvement in left ventricle ejection fraction (LVEF), an important measure of cardiac function.

 

April 7, 2005

Wex Receives €2,000,000 From Co-Development Partner

Vancouver, (April 7, 2005) – WEX Pharmaceuticals Inc. (“WEX” or the “Company”) is pleased to announce that it has received a €2,000,000 payment from its co-development partner, Laboratorios del Dr. Esteve S.A. (“ESTEVE”). This payment represents ESTEVE’s commitment to the recently completed Canadian Phase IIa clinical study of Tectinâ„¢. WEX currently has an ongoing Canadian Phase IIb/III clinical study being conducted at 24 leading pain centres.

 

April 7, 2005

Cancer Diagnostic Device Firm Perceptronix Strengthens Strategic Alliance with Asia-Based Manufacturing Partner

VANCOUVER, CANADA (April 7, 2005) – Perceptronix Medical Inc. (“Perceptronix”), a Vancouver-based medical device company focused on cancer diagnostics, announced today that it has signed a Supply Agreement with Speed Fair Co. Ltd. (“Speed Fair”) of Hong Kong.

 

April 6, 2005

MIGENIX Files Preliminary Prospectus for Unit Offering

VANCOUVER, April 6 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has filed a preliminary prospectus pursuant to which it intends to raise approximately $15 million with a syndicate of agents led by Canaccord Capital Corporation and including Dundee Securities Corporation, Octagon Capital Corporation, Pacific International Securities Inc. and Orion Securities Inc.

 

April 6, 2005

Angiotech partner receives CE Mark for three large sizes of its market- leading TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system

VANCOUVER, April 6 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner Boston Scientific Corporation (“BSC”) today announced that it has received CE Mark for three large vessel sizes (4.0mm, 4.5mm and 5.0mm) of its TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system in Europe and other international markets. BSC plans to launch the new sizes immediately and will continue to supply all sizes of its TAXUS stent systems.

 

April 5, 2005

New Facility at UBC Opens as Hub for Venture Acceleration

Vancouver, BC – Discovery Parks and the UBC University-Industry Liaison Office (UILO) are proud to announce the opening of the Accelerator Centre facility at UBC on October 28, 2004. This facility, which neighbours UILO, is part of a larger vision, which is to develop an environment that will foster the creation and growth of successful new ventures proudly rooted at UBC.

 

April 5, 2005

Protox exercises Lung Cancer Licence option with the NRC Institute for Biological Sciences and with the University of Victoria

Tuesday, April 5th, 2005 – Vancouver, British Columbia – Protox Therapeutics Inc. (‘Protox’ or the ‘Company’) announced today that it has exercised its option for an exclusive licence agreement with the National Research Council of Canada’s Institute for Biological Sciences (NRC-IBS) and the University of Victoria (UVic) Innovation and Development Corporation (IDC).

 

April 1, 2005

MIGENIX Receives $9.3 Million Investment Commitment from Technology Partnerships Canada

VANCOUVER and SAN DIEGO, April 1 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, has signed an investment agreement with the Government of Canada’s Technology Partnerships Canada (TPC) program. Under the agreement, TPC will invest up to $9.3 million in the Company’s research and development activities related to MX-2401, a novel lipopeptide candidate in preclinical development for the treatment of serious, gram-positive bacterial infections. The investment covers development of MX-2401 up to and including the completion of the first Phase III clinical trial.

 

April 1, 2005

Anormed files IND to evaluate potential of AMD3100 to repair damaged heart tissue in cardiac patients

VANCOUVER, April 1 /CNW/ – AnorMED Inc. (TSX:AOM) announced today that it has filed an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration for approval to begin its clinical program for AMD3100 in cardiac patients. The filing is the first step in evaluating the potential of AMD3100, a stem cell mobilizer, to help repair damaged heart tissue in patients who have suffered heart attacks.

 

April 1, 2005

Chromos releases fiscal 2004 results and announces restructuring to focus resources on cell line engineering

Burnaby, British Columbia, Canada – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR), a public cellular engineering and therapeutics company, today announced its financial results for the fiscal year ended December 31, 2004 and its plan to refocus resources on its cell line engineering business.

 

April 1, 2005

Cardiome to Present at Investor and Clinical Conferences

Vancouver, Canada, April 1, 2005 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that the Company will participate in various upcoming clinical and investor conferences.

 

March 31, 2005

Cardiome Pharma Copr: New Drug Application Submitted for RSD1235

Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) and its co-development partner Astellas Pharma US, Inc. today announced Astellas’ submission of a New Drug Application (NDA) to the United States Food & Drug Administration (FDA) seeking approval to market the intravenous formulation of RSD1235, an investigational new drug for the acute conversion of atrial fibrillation.

 

March 30, 2005

ID Biomedical Completes Enrollment of 1,000 Subjects for Pivotal Fluviral Clinical Trial in the U.S.

VANCOUVER, March 30 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today that it has completed the enrollment of 1,000 subjects for its Fluviral clinical trial intended to support accelerated approval in the United States. As recently announced, the Company expanded this trial from 300 subjects to 1,000 healthy adults from age 18 to 64. This randomized, double-blind, comparator-controlled study is designed to evaluate the safety and immunogenicity of Fluviral in healthy adults.

 

March 30, 2005

Forbes Medi-Tech Announces Financial Results for the 4th Quarter and Year Ended December 31, 2004

Vancouver, Canada – Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI) today announced its financial results for the fourth quarter and year ended December 31, 2004 versus the fourth quarter and year ended December 31, 2003. All amounts are in Canadian dollars unless otherwise noted.

 

March 29, 2005

Forbes Medi-Tech Announces Timing of Year End Financial Results and AGM

Vancouver, Canada Forbes Medi-Tech Inc. (TSX:FMI and NASDAQ:FMTI) today announced that it would release its financial results for the fourth quarter and year ended December 31, 2004 after market on Wednesday, March 30, 2005. A conference call and webcast to discuss these financial results will be held on Wednesday March 30, 2005 at 1:30pm PT. (4:30pm ET)

 

March 29, 2005

ARC Pharmaceuticals invited to present at Convergence: The Drug/Device Summit in Pittsburgh, PA

VANCOUVER, March 29 /CNW/ – ARC Pharmaceuticals Inc. is pleased to announce that Chris Springate, President of ARC, was invited to present at Convergence: The Drug/Device Summit in Pittsburgh, Pa, March 21-23, 2005. The progress of the Company’s lead product candidate for the treatment of surgical adhesions, ARCAD(TM), was discussed in detail.

 

March 24, 2005

Angiotech Pharmaceuticals to participate in Lehman Brothers Conference

VANCOUVER, March 24 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI, TSX: ANP), is scheduled to participate in the Lehman Brothers 8th Annual Healthcare Conference.

 

March 23, 2005

Angiotech and CABG Medical, Inc. enter exclusive license agreement to extend paclitaxel technology into coronary bypass surgery

VANCOUVER, BC and MINNEAPOLIS, MN, March 23 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced the execution of an exclusive license agreement. The exclusive license agreement provides CABG Medical (NASDAQ: CABG) with access to Angiotech’s pioneering technology to treat restenosis and proliferative disease through the local delivery of the drug paclitaxel, and to Angiotech’s extensive intellectual property portfolio related to this technology. CABG Medical will employ Angiotech’s technology in the field of coronary artery bypass grafts.

 

March 23, 2005

Cardiome Pharma Corp. completes public offering of 8.5 million common shares for gross proceeds of us$51 million

VANCOUVER, March 23 /PRNewswire-FirstCall/ – Cardiome Pharma Corp. (NASDAQ: CRME, TSX: COM) announced today that it has completed its previously announced public offering of 8,500,000 common shares. The common shares were sold at US$6.00 per share and all common shares were offered by the company. The offering resulted in total gross proceeds to the company of US$51 million.

 

March 23, 2005

First U.S. drug-eluting stent trial to treat peripheral arterial disease enrolls first patient at Stanford University Medical Center

VANCOUVER, March 23 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner Cook Inc. (“Cook”) today announced that the first patient was treated Monday at Stanford University Medical Center in a landmark clinical trial evaluating a drug-coated stent from Cook Incorporated for peripheral arterial disease (PAD), a serious medical condition that affects more than 10 million Americans each year.

 

March 22, 2005

ID Biomedical receives positive data from clinical testing of its Group-Common Pneumococcal Vaccine

VANCOUVER, March 22 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today that it has completed analysis of data obtained from several Phase 1 clinical studies of its Pneumococcal Group-Common Vaccine, PGCvax(TM), in adults, elderly and toddlers. PGCvax is being developed to prevent invasive diseases, including meningitis, caused by the bacteria Streptococcus pneumoniae (also known as the pneumococcus).

 

March 22, 2005

Demegen Licenses Compounds for Oral Diseases to Pacgen Biopharmaceuticals

PITTSBURGH, March 22 /PRNewswire-FirstCall/ — Demegen, Inc. (PRVG), a biotechnology company specializing in the development of peptides for the treatment of infectious diseases, announced today it had granted a license to Pacgen Biopharmaceuticals Corporation (Pacgen) for certain Demegen peptides for prescription and over-the-counter pharmaceutical products to treat oral diseases.

 

March 21, 2005

Stressgen’s HspE7 Treatment Showed Higher Than Expected Complete Response Rate Among Women with High Grade Cervical Dysplasia

MIAMI BEACH, FL, March 21 /CNW/ – Stressgen Biotechnologies (TSX:SSB) announced today that data from a Phase II study in high grade cervical dysplasia using HspE7, the Company’s lead drug product candidate for human papillomavirus (HPV)-related diseases, was presented by Mark Einstein, M.D., of Albert Einstein College of Medicine on behalf of the New York Phase II Consortium and under the sponsorship of the National Cancer Institute (NCI) at the Society of Gynecologic Oncologists Annual Meeting on Women’s Cancer(TM).

 

March 21, 2005

UBC Team Sequence Largest Bacterial Genome to Date: May Facilitate Clean Up of Hazardous Waste and Development of New Antibiotics

An international team led by three UBC microbiologists has completed the sequencing and annotation of the genome of Rhodococcus sp. RHA1, a soil bacterium, which is the largest bacterial genome sequenced to date. It is the first genome of a Rhodococcus to be completely sequenced, and the first bacterial genome to be entirely sequenced and annotated in Canada.

 

March 18, 2005

Abgenix Files Resale Registration Statement

FREMONT, Calif., March 17 /PRNewswire-FirstCall/ — Abgenix, Inc. (Nasdaq: ABGX), a biopharmaceutical company focused on development of antibody therapeutics, announced today it has filed a resale registration statement on Form S-3 with the U.S. Securities and Exchange Commission covering its 1.75 percent Convertible Senior Notes due December 2011 and the common stock issuable upon conversion of the notes.

 

March 18, 2005

Panitumumab Pivotal Trial Completes Patient Enrollment

FREMONT, Calif., March 18 /PRNewswire-FirstCall/ — Abgenix, Inc. (Nasdaq: ABGX) today announced that Amgen has completed patient enrollment in a pivotal trial evaluating panitumumab, an experimental fully human monoclonal antibody, as monotherapy for metastatic colorectal cancer patients who have failed standard chemotherapy.

 

March 17, 2005

Enzon Pharmaceuticals Terminates Marqibo Agreement

VANCOUVER, BC – Inex Pharmaceuticals Corporation (INEX; TSX:IEX) announced today that it has reached an agreement with Enzon Pharmaceuticals Inc. (“Enzon”; NASDAQ: ENZN) to terminate the development and commercialization agreement for Marqibo (vincristine sulfate liposomes injection) effective immediately.

 

March 17, 2005

INEX Releases 2004 Operating Results & 2005 Milestones

VANCOUVER, BC – Inex Pharmaceuticals Corporation (“INEX”; TSE: IEX) announced today as part of its 2004 audited operating results that its focused objectives and cash position will enable the Company to design a clinical development program and a new commercialization path for its lead anticancer product Marqiboâ„¢ as well as consider strategic options for its pipeline.

 

March 16, 2005

Collaboration Between Esteve and Wex Grows to Co-Development

Vancouver, (March 16, 2005) – WEX Pharmaceuticals Inc. (WEX or the Company) is pleased to announce that it has mutually decided with its European partner, Laboratorios del Dr. Esteve S.A. (ESTEVE) to make certain amendments to the previously executed License and Collaboration Agreement relating to the Company’s products Tectin (TM), Tetrodin(TM) and Tocudin(TM).

 

March 16, 2005

OncoGenex Technologies and Isis Pharmaceuticals Expand Antisense Drug Development Partnershp in Oncology

VANCOUVER, British Columbia, and CARLSBAD, Calif., March 16 /PRNewswire- FirstCall/ — OncoGenex Technologies Inc., and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today they have broadened their antisense drug development partnership to allow for the development of two additional second- generation antisense anti-cancer drug candidates.

 

March 16, 2005

AnorMED initiates enrollment into phase I/II study for new HIV entry inhibitor

VANCOUVER, March 16 /CNW/ – AnorMED Inc. (TSX:AOM) announced today initiation of enrollment into a Phase Ib/IIa trial to evaluate the potential of AMD070, an oral CXCR4 HIV entry inhibitor, in HIV-infected patients. The Company’s clinical program for AMD070 is being conducted by leading investigators at the U.S. Adult AIDS Clinical Trials Group (ACTG), which is supported by the National Institute of Allergy and Infectious Diseases at the National Institute of Health.

 

March 16, 2005

ID Biomedical reports fiscal 2004 year end results

VANCOUVER, March 16 /PRNewswire-FirstCall/ – ID Biomedical Corporation (TSX: IDB – News; NASDAQ: IDBE – News) announced today financial results for the year ended December 31, 2004, which included record revenues of CDN$53.7 million.

 

March 15, 2005

Chromos to acquire Anosys, Inc.

BURNABY, BC, and SEATTLE, March 15 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) today announced it has entered into a Letter of Intent to acquire Anosys Inc. (“Anosys”). Chromos will issue shares, warrants and / or convertible notes to acquire all outstanding shares of Anosys. Chromos expects to finalize a definitive agreement for the transaction before March 25th. Completion of the acquisition is subject to satisfactory due diligence, execution of definitive agreements, and approval by Anosys shareholders and regulatory authorities.

 

March 15, 2005

ID Biomedical to pursue U.S. accelerated approval process for its influenza vaccine

VANCOUVER, March 15 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today that it has been advised by the United States Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) that the Company’s injectable influenza vaccine is eligible for accelerated approval and priority review mechanisms, allowing possible licensure of the vaccine in time to manufacture product for the 2006/07 season.

 

March 14, 2005

ID Biomedical announces 2004 year end earnings release date and conference call

VANCOUVER, March 14 /CNW/ – ID Biomedical Corporation (TSX: IDB; NASDAQ: IDBE) announced today that it will report its 2004 year end results on Wednesday, March 16, 2005, at 4:00 pm EST. The Company will follow the results with a conference call/webcast at 5:00 pm EST / 2:00 pm PST. The call can be accessed by dialing (604) 677-8677 or by logging onto the Company’s website at www.idbiomedical.com.

 

March 14, 2005

Inex Pharmaceuticals Conference Call Notification 2004 Year End Operating Results

VANCOUVER – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that it will hold a conference call and webcast on Thursday, March 17, 2005 at 9:00 a.m. PST (12:00 noon EST) to discuss 2004 year end operating results and to provide an update on developments at the Company.

 

March 14, 2005

Stressgen Biotechnologies Announces 2004 Financial Results

SAN DIEGO, CA, March 14 /CNW/ – Stressgen Biotechnologies Corporation(TSX: SSB) announced today financial results for the year ended December 31, 2004. All amounts, unless specified otherwise, are in Canadiandollars.

 

March 14, 2005

Abgenix and Genentech Extend Antibody Technology Licensing Agreement

FREMONT, Calif., March 14 /PRNewswire-FirstCall/ — Abgenix, Inc. (Nasdaq: ABGX) announced today that Genentech, Inc. (NYSE: DNA) has exercised its option to extend its technology licensing agreement with Abgenix for an additional three years.

 

March 14, 2005

Allon CSO presents pre-clinical data to Alzheimer’s/Parkinson’s conference in Sorrento, Italy

VANCOUVER, March 14 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company(TM), has presented pre-clinical data to an international conference on Alzheimer’s and Parkinson’s disease that helps explain how the company’s proprietary lead compound AL-108 protects brain cells from degenerative diseases.

 

March 11, 2005

Ondine Biopharma reports clinical study preliminary findings

Ondine Biopharma Corporation (TSX: OBP; AIM: OBP) (“Ondine”) announced today preliminary findings from its ongoing clinical study evaluating PhotoDynamic Disinfection (PDD) for the treatment of periodontal disease. This initial study is designed to evaluate safety data and efficacy trends in a limited number of patients prior to a larger, pivotal trial expected to commence in the second half of this year.

 

March 10, 2005

Ondine Biopharma Corporation Announces the new Year End Financial Results for the Six Month Period Ending December 31, 2004

VANCOUVER, March 10 /CNW/ – Ondine Biopharma Corporation (TSX: OBP;AIM: OBP) (“Ondine”) announced today its financial results for the six month period ended December 31, 2004. As a result of the change in the Company’s year end to December 31 from June 30, the results for the six months ended December 31, 2004 are compared to the twelve month period ended June 30, 2004.

 

March 10, 2005

MIGENIX Reports Third Quarter Fiscal Year 2005 Results

VANCOUVER and SAN DIEGO, March 10 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, provides results for the three and nine month periods ended January 31, 2005 and an update on certain programs.

 

March 9, 2005

Aspreva Pharmaceuticals Announces Closing of IPO

Aspreva Pharmaceuticals Corporation (Nasdaq: ASPV; TSX: ASV) today announced the closing of its initial public offering of 8,280,000 common shares at US$11.00 (C$13.68) per share. The shares are listed on the Nasdaq National Market under the trading symbol ASPV and the Toronto Stock Exchange under the trading symbol ASV.

 

March 9, 2005

Wex Appoints Chief Medical Officer

Vancouver, (March 9, 2005) – WEX Pharmaceuticals Inc. WEX (TSX: WXI) is pleased to announce the appointment of Dr. Jean Bourgouin as its new Chief Medical Officer in charge of all clinical, non-clinical and discovery programs. Dr. Jean Bourgouin brings to WEX over 25 years experience in global clinical drug development within the pharmaceutical industry in a wide range of clinical and project leadership positions.

 

March 8, 2005

Allon Therapeutics compounds show potential to treat eye disease

VANCOUVER, March 8 /CNW/ – Two proprietary compounds of Allon Therapeutics Inc. (TSX-V: “NPC”), “The Neuro Protection Company”, have the potential to become new treatments for diseases of the optic nerve and retina — including glaucoma, the second most common cause of blindness in the United States — according to results of a preclinical study published in the March issue of Investigative Opthalmology & Visual Science.

 

March 7, 2005

Abgenix Appoints Donald R. Joseph as Senior Vice President, General Counsel and Secretary

FREMONT, Calif., March 4 /PRNewswire-FirstCall/ — Abgenix, Inc. (Nasdaq: ABGX), a biopharmaceutical company focused on development of antibody therapeutics, announced today the appointment of Donald R. Joseph as Senior Vice President, General Counsel and Secretary.

 

March 6, 2005

TAXUS V demonstrates excellent safety and efficacy results in most challenging lesions and high-risk patients

VANCOUVER, BC and ORLANDO, FL, March 6 /CNW/ – Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”)today announced nine-month results from its TAXUS V clinical trial, confirmingthe safety and efficacy of the TAXUS(R) Express2(TM) paclitaxel-elutingcoronary stent system for the treatment of coronary artery disease.

 

March 6, 2005

JNJ REALITY Trial fails to meet endpoints

VANCOUVER, BC and ORLANDO, FL, March 6 /CNW/ – Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI, TSX: ANP) today announced that results from the REALITYTrial, a head-to-head trial sponsored by Johnson & Johnson (“JNJ”) comparingthe JNJ CYPHER(R) stent and the TAXUS(R) stent, were presented today at theAmerican College of Cardiology Annual Scientific Session. The trial failed tomeet its primary endpoint.

 

March 3, 2005

Aspreva Pharmaceuticals Announces Pricing of Initial Public Offering at US$11.00 (C$13.68) per Share

VICTORIA, March 3 /PRNewswire-FirstCall/ – Aspreva Pharmaceuticals Corporation (Nasdaq: ASPV – News; TSX: ASV – News) today announced the initial public offering of 7,200,000 shares of its common shares at a price of US$11.00 (C$13.68) per share.

 

March 2, 2005

Protox appoints Fahar Merchant as Vice President, Corporate Development

Wednesday, March 2nd, 2005 – Vancouver, British Columbia – Protox Therapeutics Inc. (“Protox” or the “Company”) today announced that Fahar Merchant, PhD, has been appointed Vice President, Corporate Development of the Company. Dr. Merchant will be responsible for both in-licensing and out-licensing activities associated with the Company’s targeted toxin platform and negotiating other strategic alliances.

 

March 2, 2005

Forbes Medi-Tech Receives European Approval for Reducol(tm) in Seven Major Food Groups

Vancouver, BC — Forbes Medi-Tech Inc. (TSX: FMI; NASDAQ: FMTI) announced today that the Company received an opinion of substantial equivalence from European regulatory authorities allowing Forbes to market its cholesterol-lowering ingredient, Reducol(tm), in a variety of approved food groups including: yellow fat spreads (margarine), fermented milk type products, soy drinks, low-fat cheese type products, yoghurt type products, spicy sauces, and salad dressings.

 

March 2, 2005

Allon completes dosing in Phase Ia human clinical trials for lead product

VANCOUVER , March 2 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), “The Neuro Protection Company”, announced today it has completed dosing for its Phase Ia human clinical trial evaluating the company’s lead product AL-108 as a treatment for Alzheimer’s disease.

 

March 2, 2005

MIGENIX Third Quarter Fiscal 2005 Financial Results Conference Call & Web Cast Notification

VANCOUVER and SAN DIEGO, March 2 /CNW/ – MIGENIX Inc. (TSX: MGI;OTC: MGIFF), a clinical-stage developer of drugs for infectious and degenerative diseases, will host a conference call and web cast on Thursday, March 10, 2005 at 11:00 a.m. ET (8:00 a.m. PT) to discuss financial results for the third quarter of Fiscal 2005 ended January 31, 2005 and provide an update on company activities.

 

February 28, 2005

Angiotech Pharmaceuticals, Inc. announces results for the quarter and year ended December 31, 2004

VANCOUVER, Feb. 28 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP) today announced financial results for the quarter and year ended December 31, 2004. Amounts, unless specified otherwise, are expressed in U.S. dollars.

 

February 24, 2005

Stressgen Files Canadian Amended and Restated Preliminary Prospectus for Offering of Common Shares in Conjunction with U.S. Private Placement

VICTORIA, BC, and SAN DIEGO, CA, Feb. 24 /CNW/ – Stressgen Biotechnologies (TSX:SSB) announced today that the corporation has filed an amended and restated preliminary prospectus in Canada. The filing amends and restates a preliminary prospectus originally filed on October 4, 2004. The prospectus includes updated financial information to September 30, 2004, and discusses recent developments further detailed on the attachment to this release.

 

February 23, 2005

QLT Announces 2004 Results and Outlook for 2005

VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) today reported its financial results for the fourth quarter ended December 31, 2004 and full year 2004 and issued its guidance for 2005, reflecting the merger of QLT Inc. and Atrix Laboratories, Inc., which closed November 19, 2004. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.

 

February 23, 2005

Ondine Biopharma Announces Management and Board Changes

VANCOUVER, Feb. 23 /CNW/ – Ondine Biopharma Corporation (TSX:OBP, AIM: OBP) (“Ondine” or the “Company”) announces that, effective today, Mr. Douglass Watson has, for personal reasons, resigned from his positions as the President, Chief Executive Officer and a director of the Company. The Board wishes to thank Mr. Watson for his valuable contributions to the Company.

 

February 23, 2005

Cardiome Receives US$6 Million Milestone Payment

Vancouver, Canada, February 23, 2005 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that it has received a US$6 million milestone payment from its co-development partner, Fujisawa Healthcare Inc. The milestone payment was triggered by the successful completion of ACT 1, the first of three Phase 3 clinical trials for Cardiome’s lead antiarrhythmic product, intravenous RSD1235.

 

February 23, 2005

Angiotech partner announces start of enrollment in world’s largest drug-eluting stent registry

VANCOUVER, Feb. 23 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”), announced today the start of enrollment in the world’s largest drug-eluting stent registry. The TAXUS OLYMPIC registry plans to enroll more than 30,000 patients at more than 600 centers in the United States, Europe and other international locations.

 

February 22, 2005

Angiotech partner announces completion of enrollment in pivotal clinical trial for next-generation paclitaxel-eluting coronary stent system

VANCOUVER, Feb. 22 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“BSC”), announced today that it has completed enrollment in its ATLAS clinical trial. ATLAS is the first trial using Boston Scientific’s new Liberte(TM) coronary stent as a platform for its paclitaxel-eluting coronary stent system.

 

February 22, 2005

Abgenix Announces 2004 Fourth Quarter and Full Year Financial Results

FREMONT, Calif., Feb. 22 /PRNewswire-FirstCall/ — Abgenix, Inc. (Nasdaq: ABGX) today reported financial results for the fourth quarter and full year ended December 31, 2004.

 

February 18, 2005

Angiotech to webcast conference call discussing year end 2004 financial results

VANCOUVER, Feb. 18 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), will webcast its conference call discussing financial results for the fourth quarter ended December 31st, 2004 on Monday, February 28th , 2005 at 2:00 PM PST (5:00 PM EST).

 

February 18, 2005

ACZONETM Data Demonstrates Reduction in Number and Severity of Acne Lesions

VANCOUVER, CANADA—QLT Inc. (NASDAQ: QLTI; TSX: QLT) announces data from three clinical studies presented at the American Academy of Dermatology conference in New Orleans demonstrating that the Company’s acne product AczoneTM (5% dapsone topical gel) reduces the number and severity of all lesion types in acne patients with no significant safety issues.

 

February 18, 2005

Angiotech addresses legal proceedings

VANCOUVER, Feb. 18 /CNW/ – As previously announced on February 1st, 2005,Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) along with itscorporate partner Boston Scientific initiated legal proceedings in theNetherlands against Conor Medsystems after the validity of one of Angiotech’sEuropean patents (No. EP 0 706 376) was upheld by the European Patent OfficeOpposition Division.

 

February 18, 2005

Perceptronix Earns US Patent For Lung Cancer Detection Technology

 

February 17, 2005

Commercial availability of QLT’s Eligard(R) 6-month formulation brings new treatment option for advanced prostate cancer

VANCOUVER, Feb. 17 /PRNewswire-FirstCall/ – QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced today the commercial availability in the United States of its product Eligard(R) 45mg (leuprolide acetate for injectable suspension) six- month formulation, a palliative treatment of advanced prostate cancer.

 

February 16, 2005

Chromos and AppTec announce strategic alliance to provide integrated services for biopharmaceutical manufacturing

BURNABY, BC, and ST. PAUL, MN, Feb. 16 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) and AppTec Laboratory Services, Inc. (“AppTec”) today announced a strategic alliance for providing the biopharmaceutical industry with a broad range of cell line engineering and contract manufacturing services.

 

February 15, 2005

Cardiome to Present at CIBC Investor Conference

Vancouver, Canada, February 15, 2005 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that Bob Rieder, President & CEO, will present at the 8th Annual CIBC World Markets Whistler Institutional Investor Conference. Mr. Rieder will give a 30 minute presentation from 3:30 – 4:00 pm PST on Thursday February 17th. The live webcast of Mr. Rieder’s presentation will be available for 30 days on Cardiome’s website at http://www.cardiome.com/investor/events/.

 

February 14, 2005

Wex Reports Financial Results for Third Quarter Ended December 31, 2004

Vancouver, February 14, 2005 – Wex Pharmaceuticals Inc. (“WEX” or the “Company”) today reported interim financial results for the three and nine month periods ended December 31, 2004. The unaudited interim consolidated financial statements presented here have been prepared in accordance with Canad ian generally accepted accounting principles for interim financial information (“Canadian GAAP”). All figures herein are denoted in Canad ian dollars unless otherwise specified.

 

February 11, 2005

Cardiome Reports Oxypurinol Clinical Results

Vancouver, Canada, February 11, 2005 Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) today announced results for the physician-sponsored “La Plata” clinical study for oxypurinol in congestive heart failure (CHF) patients. The blinded, placebo-controlled 60-patient study showed a statistically-significant improvement in an important measurement of cardiac function, the left ventricle ejection fraction (LVEF).

 

February 11, 2005

Angiotech Pharmaceuticals to participate in CIBC Investor Conference

VANCOUVER, Feb. 11 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the 8th Annual CIBC World Markets Whistler Institutional Investor Conference.

 

February 9, 2005

MIGENIX releases CEO Message – provides update on major clinical programs

VANCOUVER, BC, and SAN DIEGO, CA, Feb. 9 /CNW/ – MIGENIX Inc. (TSX: MGI; OTC: MGIFF), a developer of drugs for infectious and degenerative diseases, has issued its 14th Quarterly CEO Message from Jim DeMesa, MD, President & CEO.

 

February 9, 2005

Inflazyme Pharmaceuticals Announces Financial Results for Quarter Ended December 31, 2004

VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) today announced its third quarter financial results for the period ended December 31, 2004.

 

February 9, 2005

BC Government commits $100 million to MSFHR

Vancouver – BC’s health research community is receiving a significant boost in provincial support, thanks to the Government of British Columbia’s pledge of $100 million to the Michael Smith Foundation for Health Research (MSFHR).

 

February 8, 2005

Genome BC Congratulates Genologics

As GenoLogics Life Sciences Software Inc. celebrated a $6.3 million round of financing, Alan Winter, CEO of Genome British Columbia offered congratulations. “As a partner in the University of Victoria- Genome British Columbia Proteomics Centre, where the life sciences bioinfomatics software was developed, we are pleased to see the results of funding support that was provided two years ago”, says Winter.

 

February 7, 2005

Wex Pharmaceuticals Inc. announces the appointment of Michael Perri as its new Chief Financial Officer

Vancouver, (February 7, 2005) – Wex Pharmaceuticals Inc. WEX (TSX: WXI) is pleased to announce the appointment of Michael Perri as its new Chief Financial Officer. Bob MacGregor will relinquish his role as the interim Chief Financial Officer and assume the position as Head of Finance.

 

February 4, 2005

Gary Ingenito Joins Angiotech as Senior Vice President, Clinical Development and Regulatory Affairs

VANCOUVER, Feb. 4 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), a specialty pharmaceutical company focused on drug-eluting medical devices and biomaterials, today announced the appointment of Gary Ingenito, MD, PhD to Senior Vice President, Clinical Development & Regulatory Affairs, effective immediately.

 

February 4, 2005

Cardiome reports additional act 1 clinical results

Vancouver, Canada, and Deerfield, IL, USA, February 4th, 2005 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) and its co-development partner Fujisawa Healthcare, Inc. today announced additional results from their recently completed 416-patient atrial arrhythmia (“AF”) clinical study, called ACT 1. Top-line results for ACT 1 were announced on December 20, 2004, showing that the drug converted 52% of recent-onset patients to normal heart rhythm, while causing no side-effect arrhythmias. Data released today covered three aspects of the clinical data that were not available at the time of the announcement in December: the time to conversion, the rate of relapse to AF, and the conversion rate in the atrial flutter sub-group.

 

February 3, 2005

Cardiome to Hold Conference Call Discussing Additional ACT 1 Data

Vancouver, Canada, February 3, 2005 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that it will hold a teleconference and webcast on Friday February 4th at 1 pm EST, 10am PST to discuss additional data from the recently completed phase 3 atrial arrhythmia study, ACT 1. Cardiome will provide details regarding time to conversion and relapse rate for the ACT 1 trial, as well as safety and efficacy results for the atrial flutter subset. Cardiome will release the additional data prior to the conference call on Friday.

 

February 3, 2005

AnorMED announces fiscal 2005 third quarter results and upcoming key events

VANCOUVER, Feb. 3 /CNW/ – AnorMED Inc. (TSX:AOM) today reported financial results for its third quarter ended December 31, 2004. AnorMED recorded net income of $15,848,000 ($0.50 per common share) in this quarter. This is in comparison to the net losses incurred in the third fiscal quarter of 2004 of $4,409,000 ($0.17 per common share) and in the previous quarter, ended September 30, 2004 of $6,584,000 ($0.21 per common share).

 

February 3, 2005

GenoLogics Secures U.S. $5 million in Funding from OVP Venture Partners, Yaletown Venture Partners and Growthworks

VICTORIA, B.C. – February 3, 2005 – GenoLogics Life Sciences Software Inc., developer of an open bioinformatics software platform that assists life science and pharmaceutical research laboratories manage, integrate and analyze enormous volumes of scientific data, today announced that it has completed a $5 million (U.S.) round of financing.

 

February 1, 2005

Forbes Medi-Tech Initiates Toxicity Study on FM-VP4 to Support US Phase II trial for Cholesterol-Lowering Drug

Vancouver, British Columbia –Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced that it has commenced a 90-day toxicity study for its cholesterol-lowering drug, FM-VP4. This study is required to support an extended US Phase II human trial planned for later this year. Results from an earlier 28 day European trial of FM-VP4 suggest that LDL cholesterol levels may continue to decrease when FM-VP4 is given to patients for longer than 4 weeks and that optimal efficacy may not have been achieved.

 

February 1, 2005

Angiotech announces joint law suit against Conor Medsystems

VANCOUVER, Feb. 1 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that they along with corporate partner Boston Scientific have initiated legal proceedings in the Netherlands against Conor Medsystems.

 

January 31, 2005

Allon Therapeutics scientist presents preclinical data to U.S. neurologists

VANCOUVER, Jan. 31 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company, has presented preclinical data to two American neurology groups showing that its proprietary lead compound AL-108 has properties that protect brain cells from degenerative diseases.

 

January 31, 2005

Angiotech partner says physician feedback is extremely positive as it completes initial launch of TAXUS(R) Liberte(TM) paclitaxel-eluting stent system

VANCOUVER, Jan. 31 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,TSX: ANP) corporate partner, Boston Scientific (“BSC”), announced today thatit has completed the initial launch of its TAXUS(R) Liberte(TM) paclitaxel-eluting coronary stent system. On January 17, BSC announced that it hadlaunched the next-generation stent system in 18 countries. The new product isnow fully launched in those countries.

 

January 27, 2005

Cardiome Appoints Dr. Charles Fisher as Chief Medical Officer and Executive Vice President

Vancouver, Canada, January 27, 2005 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced the appointment of Dr. Charles Fisher to the position of Chief Medical Officer and Executive Vice President, Clinical and Regulatory Affairs. Dr. Fisher will be responsible for overseeing and implementing Cardiome’s clinical and regulatory programs and contributing to new product development.

 

January 26, 2005

Cardiome to Present at Piper Jaffray Health Care Conference

Vancouver, Canada, January 26, 2005 Cardiome Pharma Corp (NASDAQ: CRME) (TSX: COM) today announced that Bob Rieder, President & CEO, will present at the Piper Jaffray Health Care Conference at The Pierre Hotel in New York. Mr. Rieder will present at 1:00 pm EST on Thursday January 27th. A webcast of Mr. Rieder’s presentation will be available on Cardiome’s website at http://www.cardiome.com/investor/events/.

 

January 25, 2005

Allon begins Phase I human clinical trials for lead product AL-108

VANCOUVER, Jan. 25 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company, announced today it has commenced its Phase I human clinical trial evaluating the company’s lead product AL-108 as a treatment for Alzheimer’s disease.

 

January 25, 2005

AnorMED announces patient enrollment into pivotal Phase III trials for new stem cell transplant drug candidate

VANCOUVER, Jan. 25 /CNW/ – AnorMED Inc. (TSX:AOM) announced today the start of patient enrollment into its Phase III clinical program for AMD3100, a stem cell mobilizer and potential new agent in stem cell transplantation for cancer patients. The two Phase III trials will evaluate AMD3100 in a standard stem cell mobilization regimen in non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM) patients undergoing stem cell transplantation.

 

January 25, 2005

Welichem appoints Director, Project Management

Burnaby-January 25, 2005- Welichem Biotech Inc. is pleased to announce the appointment of Marianne Smyth as Director, Project Management, effective immediately.

 

January 25, 2005

Local Cancer Diagnostics Firm Signs Agreement with China-based Firm During Trade Mission

Vancouver, Canada, 25 January, 2005 – Perceptronix Medical Inc. (“Perceptronix”) announced today that it has signed a Memorandum of Understanding (“MOU”) with Speed Fair Co. Ltd. (“Speed Fair”) as part of the Hong Kong contract signing ceremony of the Prime Minister’s Team Canada Trade Mission to the People’s Republic of China.

 

January 24, 2005

European Patent office maintains validity of Angiotech’s paclitaxel-eluting stent patent

VANCOUVER, Jan. 24 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced a favorable decision on its European Patent (No. 0706 376) from the European Patent Office Opposition Division.

 

January 24, 2005

Aspreva Pharmaceuticals Corporation Plans Initial Public Offering

Aspreva Pharmaceuticals Corporation announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission and a preliminary prospectus with Canadian provincial regulatory securities authorities for a proposed initial public offering of its common shares.

 

January 20, 2005

Abgenix Appoints Kristen M. Anderson as Senior Vice President of Human Resources

FREMONT, Calif.–(BUSINESS WIRE)–Jan. 20, 2005–Abgenix, Inc. (Nasdaq:ABGX) announced today the appointment of Kristen M. Anderson as Senior Vice President of Human Resources effective January 24.

 

January 20, 2005

AnorMED Announces New Appointment to Board of Directors

Vancouver, British Columbia – AnorMED Inc. announced today that Eve E. Slater M.D., has been appointed to AnorMED’s Board of Directors. Dr. Slater is board certified in both internal medicine and cardiology and has extensive experience in the pharmaceutical industry, including 19 years in Senior Management at Merck Research Laboratories.

 

January 19, 2005

Angiotech partner announces implantation of millionth TAXUS(R) Express2(TM) coronary stent system

VANCOUVER, Jan. 19 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI, TSX:ANP) corporate partner, Boston Scientific (“Boston”), today announced the implantation of its millionth TAXUS(R) Express2(TM) paclitaxel-eluting coronary stent system, marking a major milestone for Boston Scientific and for the treatment of coronary artery disease.

 

January 19, 2005

FDA Issues Not Approvable Letter for Marqiboâ„¢

Vancouver, BC – Inex Pharmaceuticals Corporation (“INEX”; TSX: IEX) announced today that United States Food and Drug Administration (FDA) provided an action letter detailing that the anticancer drug Marqiboâ„¢ (vincristine sulfate liposomes injection) is “not approvable” under the FDA’s accelerated approval regulations based on the phase 2 clinical trial data submitted.

 

January 17, 2005

Abgenix to Receive Milestone Payment from Amgen for Advancement of Product Candidate into Clinical Trials; Eleventh XenoMouse Antibody Advances to the

FREMONT, Calif.–(BUSINESS WIRE)–Jan. 13, 2005–Abgenix, Inc. (Nasdaq:ABGX) announced today that the company will receive a milestone payment from Amgen triggered by Amgen’s advancement of an undisclosed antibody, created using Abgenix’s proprietary XenoMouse(R) technology, into clinical trials. This is the eleventh antibody generated with Abgenix’s technology to move into the clinic phase.

 

January 17, 2005

Angiotech partner is first to market with next-generation drug-eluting stent system

VANCOUVER, Jan. 17 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) corporate partner, Boston Scientific (“Boston”), today announced that Boston has launched its TAXUS(TM) Liberte(TM) paclitaxel-eluting coronary stent system in 18 countries. The TAXUS Liberte stent system features Boston Scientific’s next-generation Liberte(TM) coronary stent.

 

January 14, 2005

Chromos announces completion of private placement

BURNABY, BC and SEATTLE, WA, Jan. 14 /CNW/ – Chromos Molecular Systems Inc. (“Chromos”; TSX: CHR) announced today that it has completed the private placement of 2,215,085 units at $0.48 per share for total gross proceeds of $1,063,241.

 

January 14, 2005

Dragon Completes Acquisition of Oriental Wave Holding Ltd. and Announces Appointment of Key Management Team

Vancouver, BC- January 13, 2005. Dragon Pharmaceutical Inc. (OTC BB: DRUG; TSX: DDD; BBSE: DRP) (“the Company”) is pleased to announce that it has completed the acquisition of Oriental Wave Holding Ltd.

 

January 13, 2005

Allon receives FDA approval to begin Phase I human clinical trials

VANCOUVER, Jan. 13 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), The Neuro Protection Company, announced today it has received approval from the United States Food and Drug Administration (FDA) to begin a Phase I human clinical trial evaluating the company’s lead product AL-108 as a treatment for Alzheimer’s disease.

 

January 12, 2005

Forbes Medi-Tech Provides 2005 Revenue Guidance

Vancouver, British Columbia –Forbes Medi-Tech Inc. (TSE:FMI and NASDAQ:FMTI) today announced revenue guidance of CDN$21 to $22 million for fiscal 2005 for the period ending December 31, 2005. This anticipated revenue represents a minimum 20% growth versus 2004’s expected revenue of approximately CDN$17.5 million. The Company’s projected 2004 revenue exceeds the previous guidance of CDN$16.5 announced in December 2004. This increase is due to strong sales of the Company’s Reducol(tm) and Phyto-S Sterols in November and December.

 

January 12, 2005

Inflazyme Announces Management Changes; Kevin Mullane is appointed interim CEO

VANCOUVER, B.C., CANADA – Inflazyme Pharmaceuticals Ltd. (TSX: IZP) announced today that Ian McBeath, President and CEO, is leaving Inflazyme to pursue other opportunities. The Board has appointed Kevin Mullane, formerly Senior Vice President, Research & Development, as interim CEO, effective immediately.

 

January 12, 2005

Abgenix to Receive Milestone Payment from Chiron for Advancement of Oncology Antibody; Tenth XenoMouse Antibody Advances to the Clinical Phase

FREMONT, Calif.–(BUSINESS WIRE)–Jan. 12, 2005–Abgenix, Inc. (Nasdaq:ABGX) announced today that the company will receive a milestone payment from Chiron Corporation triggered by Chiron’s filing of an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for the novel oncology compound CHIR-12.12, a fully human antagonist antibody targeting CD40. The antibody was created by Chiron using proprietary XenoMouse(R) technology licensed from Abgenix.

 

January 11, 2005

Angiotech and Orthovita announce commercial launch of Vitagel(TM)

VANCOUVER, BC and MALVERN, PA, Jan. 11 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) and Orthovita, Inc. (NASDAQ: VITA) today announced that the companies have begun the official commercial launch of Vitagel(TM). Orthovita has initiated distribution through its 40 direct sales representatives and roughly 20 independent distributors. The direct representatives will have a launch base that extends over 500 hospitals. As part of the Cohesion consolidation, Angiotech expects a full transfer of production capabilities from the Palo Alto facility to Orthovita’s Malvern facility to be complete by Q3:05.

 

January 10, 2005

AVID System Receives European Certification

For Immediate Release January 10, 2004: Vancouver, Canada – MDX Medical Inc. (TSXV: MDX) MDX Medical Inc. (TSXV: MDX) MDX is pleased to report that the AVID System, in partnership with MDX Medicals’ design and manufacturing partner, Starfish Product Engineering Inc., has received an EC Certificate and corresponding CE Marking and is now approved for sale in Europe. The AVID System is classified as a Class I Medical Device under Annex V of the Medical Device Directive (MDD).

 

January 7, 2005

Active Pass Pharmaceuticals, Inc. Announces the Appointment of Brett Gannon to Board

Active Pass Pharmaceuticals, Inc. today announced the appointment of Brett Gannon to its Board of Directors. Mr. Gannon becomes an independent Director with Active Pass Pharmaceuticals, Inc. and is also currently the CFO of Xillix Technologies Corp. He is a highly seasoned executive with more than 20 years of experience in corporate finance in Canada, the US and abroad.

 

January 5, 2005

Allon Therapeutics appoints VP Clinical Operations

VANCOUVER, Jan. 5 /CNW/ – Allon Therapeutics Inc. (TSX-V: “NPC”), the “Neuro Protection Company”, announced today the appointment of Karole Sutherland as Vice President of Clinical Operations. Sutherland was previously director of clinical operations and resource planning at QLT Inc., one of Canada’s largest biopharmaceutical companies.

 

January 5, 2005

Angiotech Pharmaceuticals to participate in JP Morgan Healthcare Conference

VANCOUVER, Jan. 5 /CNW/ – Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), is scheduled to participate in the 23rd Annual JP Morgan Healthcare Conference.

 

January 4, 2005

Wex Completes Tetrodin Trial Enrollment

Vancouver, Canada, (January 4, 2005) – Wex Pharmaceuticals Inc. (TSX:WXI) is pleased to announce that it has successfully completed the enrollment and dosing of patients during the month of December for the ongoing Phase IIa opioid dependence study with Tetrodin (Wex’s proprietary formulation of Tetrodotoxin-TTX). This randomized, double-blind, placebo-controlled study evaluates the safety and efficacy of Tetrodin in decreasing the severity of withdrawal symptoms in opiate-dependent subjects who are receiving methadone.